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ABSTRACT 
 
THE EFFECT OF MELATONIN UPON POST-ACUTE WITHDRAWAL AMONG 
MALES IN A RESIDENTIAL TREATMENT PROGRAM (M-PAWS): A 
RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL 
 
 
By 
Corry D. Bondi, Ph.D. 
December 2016 
 
Thesis supervised by Vincent J. Giannetti, Ph.D. 
 The study goal was to assess melatonin as an adjuvant treatment along with 
current pharmaco- and behavioral therapy for 28 days on weekly self-reported severity of 
anxiety, depression, stress, and sleep complaints as well as how sleep is affecting daily 
life in a sample of males in recovery from chemical dependency at a single, residential 
treatment site, Salvation Army Harbor Light Center in Pittsburgh, PA.  This study was a 
single-center, randomized, double-blind, placebo-controlled, parallel group trial of 28 
days.  Participants were randomized to melatonin (5 mg) or placebo and instructed to 
administer the intervention nightly at bedtime.  Primary self-reported outcome measures 
of severity of anxiety, depression, stress, as well as sleep complaints and how sleep is 
affecting daily life were assessed on a weekly basis with the Generalized Anxiety 
Disorder Scale (GAD-7), Personal Health Questionnaire Depression Scale (PHQ-8), 
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Perceived Stress Scale (PSS-14), and Pittsburgh Sleep Symptom Questionnaire – 
Insomnia (PSSQ-1).  Secondary outcome measures were to acquire participant histories, 
determine adherence as well as adverse events.  Seventy participants (age 21 – 65, mean 
40.4 ± 11 years) were enrolled with 24 completing the study in each group.   
Demographically, the sample consisted of those who identified as white (70%), single 
(74.3%), and with an education level of high school/G.E.D. or less (77.1%).  Intention-to-
treat analysis for all outcome measures revealed statistically significant within-groups 
differences over time for both groups.  The study failed to demonstrate statistically 
between-group differences for these measures.  Also, complete case analysis for each 
week revealed no between-group differences.  Additionally, the change from Baseline 
and Day 28 as determined by a response of an improvement of 50% or higher in scores 
for each scale revealed no significant strength of association between the groups when 
considering worst case for the loss to follow-up.  Melatonin appeared to be well tolerated 
with similar adverse events reported as placebo; however, there was a tendency to report 
more vivid dreams/nightmares as well as next day tiredness/grogginess/sleepiness.  
Clinical investigations into the use of melatonin as a treatment for depression, anxiety, 
stress, and sleep difficulties in those recovering from illicit and non-illicit drug 
dependency are limited and larger studies are warranted.  Possible future directions 
include a study design that is multicenter, the inclusion of a therapy only arm, assessing 
various doses and timelines, assessing effects in adolescents or females, or limiting 
inclusion based on prescribed medications, mental health status, medical conditions, prior 
melatonin use, and/or a specific chemical dependency.  Overall, this is the first and 
largest randomized, double-blind, placebo-controlled, parallel group trial assessing the 
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effects of melatonin upon post-acute withdrawal among males in a residential treatment 
program.  However, the various analyses indicated insufficient evidence to suggest that 
melatonin and placebo were significantly different, and it may be concluded, based upon 
the study sample, design, and its limitations, the effect of melatonin on the assessed 
measures was no different than placebo.  Due to the heterogeneity of the participants as 
evidenced by the participant histories, there exists a possibility of a Type II error that 
must be considered and not overlooked.   
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BACKGROUND 
 In the United States (U.S.), chemical dependency (i.e., substance abuse or 
substance use disorder) is a public health crisis that affects the behavioral and physical 
health of the nation.  It impacts communities, families, as well as contributes to crime, 
homelessness, and other social problems and the etiology of chronic diseases such as 
heart disease and diabetes (1, 2).  The economic burden is high with cost estimates of 
over $400 billion related to lost productivity, crime, and healthcare costs, of which, $36 
billion is directly attributed to healthcare costs (3).  Specifically, the costs associated with 
alcohol dependency are $224 billion, of which, $25 billion is attributed to healthcare 
costs while costs associated with illicit drug abuse is $193 billion and $11 billion, 
respectively (3).  Thus, finding ways to counteract this crisis is of national importance. 
According to Koob and Simon (2009), “drug addiction is a chronically relapsing 
disorder characterized by: (a) compulsion to seek and take the drug, (b) loss of control in 
limiting intake, and (c) emergence of a negative emotional state (e.g., dysphoria, anxiety, 
and irritability) when access to drug is prevented (4).”  The Substance Abuse and Mental 
Health Services Administration (SAMHSA) conducts the National Survey on Drug Use 
and Health (NSDUH), the major source of information on the prevalence, patterns, and 
consequences of illicit and non-illicit drug use and abuse in the general U.S. civilian, 
noninstitutionalized population ages 12 and older (3, 5).  According to the 2013 NSDUH, 
there were approximately 22.4 million adults (9.4% of adults) reporting using illicit drugs 
in 2013 in the past month and about 20.3 million adults (8.5% of adults) reported a past 
year substance use disorder (5).  Co-morbidity of a substance use disorder along with a 
mental health condition is common.  It is estimated that 7.7 million adults (3.2% of 
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adults) have a substance use disorder co-occurring with a mental health condition as 
defined by DSM-IV criteria (5).  Importantly, individuals with mental health issues were 
more likely to have a substance use disorder and vice versa; at least half of those who 
develop an addiction have mental health conditions (6, 7).   
 Commonly abused drugs include opiates and narcotics (e.g., heroin & narcotic 
pain medications), stimulants (e.g., amphetamine and cocaine), central nervous system 
depressants (e.g., alcohol and benzodiazepines), hallucinogens (LSD and psilocybin), and 
marijuana/hashish (6).  Specifically, 18 million adults (7.6% of adults) reported using 
marijuana or hashish followed by 4 million adults (2.5% of adults) who used prescription 
drugs (i.e., pain medications) for nonmedical reasons (5).  Marijuana use has increased 
since 2007 and remains the most commonly reported first drug used (8).  Use and abuse 
of alcohol is common with 16.2 million adults, disproportionately males, reporting being 
engaged in heavy drinking defined as “drinking five or more drinks on the same occasion 
on five or more days in the past 30 days (5, 8).”     
To alleviate the financial impact on the nation, prevention and early treatment 
programs have been shown to be beneficial.  For example, cost-benefit ratios, reported in 
the Institute of Medicine and National Research Council’s Preventing Mental, Emotional, 
and Behavioral Disorders among Young People Report – 2009, range from 1:2 to 1:10 
meaning every $1 of investment yields $2-$10 in savings (2).  As reported in the 
Treatment Episode Data Set (TEDS) of admissions and discharges from substance abuse 
treatment facilities, Whites (60%) accounted for the most admissions followed by 
African-Americans (21%) and Hispanic or Latino (14%).  The age range of 20-29 years 
(29.2%) accounted for the highest proportion of admissions while the lowest being 65 
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years or older (0.6%).  The majority of those admitted sought treatment for alcohol abuse 
(41.4%) with 18.3% of those abusing alcohol with another drug.  Twenty percent of 
admissions included heroin and other opiates, cocaine and other stimulants (17.8%), and 
marijuana (17.0%) (9). Effective treatments are available but too many individuals fail to 
get the treatment they need.  The 2013 NSDUH reported that out of 22.7 million 
individuals 12 years or older who needed treatment for alcohol or illicit drug use, only 
2.5 million received treatment at a specialty facility (5).  Individuals who needed but did 
not receive treatment, felt a need for treatment, and made an effort face many barriers 
including “no health coverage/could not afford cost (37.3%),” “not ready to stop using 
(24.5%),” “did not know where to go for treatment (9.0%),” “had health coverage but it 
did not cover treatment or did cover cost (8.2%),” and “no transportation or inconvenient 
hours (8.0%) (5).”  To address the coverage gap, the Affordable Care Act requires health 
plans to cover essential benefits such as treatments for substance abuse (7).   
Treatment begins by first identifying the problem with the overall goals to 
empower the individuals to regain control of their lives as well as to improve the 
behavioral health; both aimed at reducing the national burden of chemical dependency (5, 
10).  Because treatment is not a “one size fits all approach,” treatment programs aim to 
understand addiction, prevent relapse, and utilize various combinations of counseling, 
support networks, faith-based approaches, and medications (7, 11).  A comprehensive 
approach addresses a continuum of care including the components of health promotion, 
prevention, treatment, and recovery.  Tailoring a program to the needs and cultural 
background of the individual is the optimal approach for successful recovery (2).  The 
program needs to understand the cultural context of the individual as well as implement 
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community-based values, traditions, and customs.  Integrated treatment approaches 
focusing on treating mental health issues along with co-occurring substance use disorders 
have increased value by displaying lower costs and improved outcomes as evidenced by 
reduced substance use, decreased hospitalizations, improved mental health, increased 
housing stability, reduced arrests, and enhanced quality of life (7).  Residential treatment 
programs apply techniques to allow individuals in recovery to recognize their behaviors 
and to learn how to avoid relapse (6).  Talk therapy sessions directed by a therapist or 
counselor includes individual, group, or family in outpatient, residential, or inpatient 
settings (7, 11).  Medication-assisted treatment (MAT) seeks to control cravings and 
other symptoms of withdrawal by blocking the reward pathways or induce negative 
feelings when the addicting drug is used (7).    
Once involved in a treatment program, the individual may enter withdrawal 
therapy (detoxification) performed on an inpatient or outpatient basis in a supportive 
environment with the goal of drug cessation in a rapid and safe manner (6, 11).  
Depending on the drug, various approaches can be utilized such as titrating down the 
dose of the drug, substitution with a prescribed drug such as methadone, or combining 
treatment medications with behavioral therapy (11, 12).  Recovery as defined by 
SAMHSA is “a process of change through which individuals improve their health and 
wellness, live self-directed lives, and strive to reach their full potential (10).”  Hope is the 
foundation of recovery, and recovery is built upon the individual’s talents, strengths, 
coping abilities, resources, and inherent values.  During recovery, one may experience 
many setbacks, but the focus rests on improvements to health and wellness (10).  Overall, 
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it is important for the individual to maintain their abstinence and to cope with life 
challenges without relapse (2). 
Relapse after detoxification is extremely high if relapse prevention counseling is 
not initiated.  A number of techniques to prevent relapse include seeking help 
immediately upon drug use, avoiding high-risk environments, maintaining one’s 
treatment plan such as meeting with counselor, and going to support sessions (11).  If 
relapse occurs, a new treatment program may need to be developed or the prior treatment 
program may need to be reinstated or adjusted (12).          
Generally, individuals in recovery will transition from acute withdrawal to post-
acute withdrawal.  During post-acute withdrawal, recovered individuals will experience a 
variety of emotional and psychological symptoms (i.e., post-acute withdrawal syndrome: 
PAWS) including, but are not limited to, anxiety, sleep difficulties (e.g., sleep latency 
and duration), depression, and stress with symptoms tending to be episodic and lasting 
for up to two years.  To alleviate PAWS, individuals are usually prescribed 
pharmacotherapies and/or instructed to effectively use coping techniques of practicing 
self-care, relaxation, and cognitive therapies (13). 
Because of the symptomatology of post-acute withdrawal, melatonin therapy may 
be beneficial.  Melatonin is widely used in a non-regulated manner to alleviate insomnia 
and evidence shows that melatonin contributes to the sleep/wake cycle by initiating and 
maintaining sleep, decreasing sleep latency, improving sleep quality, next day alertness, 
and quality of life (14).  In addition to insomnia, evidence reported in the literature 
suggests that melatonin may also decrease anxiety and depressive symptoms as well as in 
individuals with co-morbid insomnia (15-19).  Melatonin (0.75 mg, nightly, 10 days) 
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improved the emotional state in anxious young individuals (15).  An intermediate-release 
formulation of melatonin, melaxen (1.5 mg, nightly, 2 weeks), decreased levels of 
depression and anxiety in a group of healthy volunteers (16).  In alcohol dependent 
patients who were not consuming alcohol for at least 14 days prior, melaxen (3 to 6 mg, 
nightly, 3 weeks) decreased anxiety (17).  Melatonin administration may be beneficial for 
improving sleep in individuals with co-morbid depression and sleep disturbances.  
Individuals with delayed sleep phase syndrome with depressive symptoms given 
melatonin (5 mg, 4 weeks) reported decreases in depression scores (18).  In an open pilot 
study, patients with depression and sleep disturbances given melatonin (3 mg orally, 
nightly, 21 days) exhibited improved sleep quality and reduced awakening within 2 to 3 
days (19) 
Alcohol dependent individuals experience difficulties with sleep latency and 
maintenance possibly due to alterations in nocturnal melatonin levels.  In a study of 
alcoholic individuals, circulating nocturnal melatonin levels were found to be lower 
during the early part of the night and had a delay in the nocturnal rise (20).  In a trial of 
alcohol dependent patients who were not consuming alcohol for at least 14 days prior, 
melaxen (3 to 6 mg, nightly, 3 weeks) improved quality, latency, duration of sleep, 
breathing during sleep, as well as decreased daily sleepiness (17).  
Research regarding nightly, orally administered melatonin has demonstrated the 
following:  is well tolerated, has no abuse potential, does not induce rebound insomnia or 
withdrawal symptoms, does not affect endogenous melatonin production, does not impact 
psychomotor, performance, mood, or cognitive functions, does not negatively affect 
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hepatic and renal function (14, 21-24).  These findings are important considering that it 
will be administered to individuals in recovery.  
There is a paucity of literature demonstrating the effects of melatonin in 
individuals experiencing PAWS.  As aforementioned, previous studies have shown that 
melatonin therapy is beneficial in alleviating anxiety, depressive symptoms, and 
insomnia.  However, no randomized, double-blind, placebo-controlled trials have been 
conducted in males who are experiencing PAWS.  The goal of this study is to test a 
therapeutic approach that incorporates the addition of melatonin to the current treatment 
program of males who are in a residential treatment program for chemical dependency.  
The purpose of the study was to assess the effect of 5 mg melatonin compared to placebo 
as an adjuvant treatment along with their current pharmaco- and behavioral therapy for 
28 days on weekly self-reported severity of anxiety, depression, stress, and sleep 
complaints as well as how sleep is affecting daily life in a sample of males in recovery 
from chemical dependency at a single, residential treatment site.   
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PURPOSE, HYPOTHESIS, and OUTCOME MEASURES 
Purpose 
The purpose of the study was to assess the effect of 5 mg melatonin compared to 
placebo as an adjuvant treatment along with their current pharmaco- and behavioral 
therapies for 28 days on weekly self-reported severity of anxiety, depression, stress, and 
sleep complaints as well as how sleep is affecting daily life in a sample of males in 
recovery from chemical dependency at a single, residential treatment site.   
Hypotheses 
 1) Melatonin along with current pharmacotherapy and behavioral treatment 
regimen will affect sleep complaints and how sleep is affecting daily life compared to 
placebo along with current pharmacotherapy and behavioral treatment regimen treatment 
regimen in males participating in a residential treatment program. 
 2) Melatonin along with current pharmacotherapy and behavioral treatment 
regimen will affect severity of anxiety, depression, and stress compared to placebo along 
with current pharmacotherapy and behavioral treatment regimen in males participating in 
a residential treatment program. 
Primary outcome measures 
 1.) To determine the effect of melatonin or placebo along with current treatment 
regimen on the change in severity of anxiety as measured by the Generalized Anxiety 
Disorder Scale (GAD-7). 
 2.) To determine the effect of melatonin or placebo along with current treatment 
regimen on the change in depressive symptoms as measured by the Personal Health 
Questionnaire Depression Scale (PHQ-8). 
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 3.) To determine the effect of melatonin or placebo along with current treatment 
regimen on the change in stress as measured by the Perceived Stress Scale (PSS-14).   
 4.) To determine the effect of melatonin or placebo along with current treatment 
regimen on the change in sleep complaints and how sleep is affecting daily life as 
measured by the Pittsburgh Sleep Symptom Questionnaire – Insomnia (PSSQ-1).  
 5.) To determine response of each individual as an improvement of 50% or higher 
in score for each scale (i.e., change from Baseline to Day 28). 
Secondary outcome measures 
 1.) To acquire participant histories (social, medical, medication, preventive, 
mental health, chemical dependency, and melatonin use, if any) 
 2.) To determine adverse events experienced while taking the intervention. 
 3.) To determine adherence to study interventions of melatonin or placebo 
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INTRODUCTION  
Substance use disorder (SUD) 
 Substance use disorder is defined as “a dependence on legal or illegal drugs or 
medication” and is diagnosed by a licensed mental health professional using criteria in 
the Statistical Manual of Mental Disorders (DSM-V), published by the American 
Psychiatric Association (11).  According to Koob and Simon (2009), “drug addiction is a 
chronically relapsing disorder characterized by: (a) compulsion to seek and take the drug, 
(b) loss of control in limiting intake, and (c) emergence of a negative emotional state 
(e.g., dysphoria, anxiety, and irritability) when access to drug is prevented (4).”  The 
following is a selected list of addiction symptoms and behaviors provided by the Mayo 
Clinic (for a more complete list consult reference): “feeling that you have to use the drug 
regularly,” “having intense urges for the drug,” “needing more of the drug to get same 
effect,” “maintain a supply of the drug,” “spending more money on the drug,” and 
“focusing more and more time and energy on getting and using the drug (11).” 
 Exposure to risk factors greatly increases the probability of becoming dependent 
on drugs and these risk factors vary with the type of drug, environment, genetics, and 
development (11, 12).  Specific factors include family history of addiction, lack of family 
involvement, male gender, initiating drug use at an early age, mental illness, peer 
pressure, and as a coping mechanism to deal with mental health issues including, but not 
limited to, depression and anxiety (11, 12).  At least half of those who become dependent 
struggle with mental health issues (6).  Moreover, the 2013 NSDUH estimated that 7.7 
million adults (3.2% of adults) had a substance use disorder along with a mental health 
issue as defined by DSM-IV criteria (5).  
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 Before becoming dependent, an individual progresses through several stages of 
drug use: experimental use, regular use, problem/risky use, and then 
addiction/dependence (6).  While chemically dependent, the individual physically needs 
the drug and larger doses of the drug in order to function normally in their daily life and 
continues to use despite the deleterious effects to their physical and mental health as well 
as to a host of societal problems including work, family, financial, and legal.  The 
individual also finds it difficult to cease drug use because discontinuance leads to 
cravings (psychological dependence) and abrupt stoppage leads to withdrawal symptoms 
(11).   
Neurobiology 
 Addiction 
To date, the reinforcing effects of addicting drugs have been linked to site of 
action - receptors and transporters, and the neurocircuitry involved - dopamine and opioid 
systems (4).  In general, the brain is a collection of neurons that communicate through the 
use of chemicals called neurotransmitters (e.g., serotonin, gamma-aminobutyric acid 
(GABA), and dopamine).  The process of addiction results in modifications in the brain 
thus resulting in changes in the behavior of the individual. Withdrawal from the addicting 
drug produces dysphoria suggesting alterations of the same neural systems involved with 
its reinforcing effects (4).  Addicting drugs act via mimicking endogenous 
neurochemicals, or by overstimulating the reward system of the brain.  For example, 
heroin and marijuana mimic endogenous neurochemicals to exert actions through 
receptors.  Dopaminergic reward systems (movement control, emotion, motivation, and 
pleasure) of the brain are modified during development of addiction and stimulants, such 
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as amphetamine and cocaine, produce effects via increasing release of dopamine or 
preventing its reuptake by the neurons from the synapse resulting in an overstimulation 
and the subsequent euphoric effects.  Over time, the neuroadaptation is to produce less 
dopamine or reduce the number of dopamine receptors thereby attenuating the effect of 
dopamine on the reward system leading to the use of more drug to prevent dysphoria – 
drug tolerance (12).  Human imaging studies revealed decreases in dopaminergic function 
(25) and the mesocorticolimbic dopamine system has been an area of focus of the 
positive reinforcing effects of addicting drugs (26).  Evidence suggests that dopamine-
independent neurocircuitry located in the nucleus accumbens and amygdala have a role in 
reward.  Research is demonstrating a role of nondopaminergic systems being involved 
with drug dependence.  Other neurochemicals are affected during addiction; for example, 
changes in glutamate levels may have a role in affecting cognition.  In summary, long-
term use of drugs leads to neuroadaptations in neurochemical levels and brain regions 
controlling a multitude of functions such as executive, cognition, and behavior (12).  
Modifications of the reward system leads to increased intake of addicting drugs, and it is 
these adaptive changes that lead to addiction.  Dopamine-dependent and -independent 
actions by dopamine, opioid peptides, serotonin, and GABA are involved with positive 
reinforcement while modifications in the reward system during dependence include the 
decreases in the aforementioned as well as recruitment of stress systems that contribute 
the negative motivational state during cessation (27).   
Cessation 
Because of the neuroadaptations that occurred in the brain during addiction, 
cessation of drug use is difficult (12).  As drug use progresses, tolerance is achieved 
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where the amount of drug needed to produce the same euphoric effect increases due to 
changes in neurocircuitry and molecular targets (e.g., receptors).  To avoid the negative 
effects of drug cessation, the individual needs the drug to prevent the physical illness, 
cravings, and dysphoria (11).  Addicting drugs produce dysphoria upon cessation 
suggesting that the neuroadaptations that occurred during addiction may involve the same 
systems involved with the positive reinforcing effects.  As such, the dysphoria and 
anxiety associated with cessation probably involve decreases in the reward system and 
recruitment of stress neurocircuitry (4).  Collectively, during drug cessation, decreases in 
levels of neurochemicals and resulting transmission occur with dopamine, serotonin, 
GABA, and dynorphin but increase levels and transmission of glutamate and 
norepinephrine suggesting that neuroadaptations occur in systems that are involved with 
positive reinforcing effects during dependence as well as systems involved with stress 
and arousal (4, 27). 
 After drug detoxification, the individual will experience less physical symptoms 
but more psychological and emotional symptoms due to the remodification of the 
neuroadaptations where the brain chemistry is attempting to return to pre-drug state.  This 
second stage of withdrawal is commonly known as PAWS.  The symptoms include, but 
are not limited to, anxiety, sleep disturbances (e.g., sleep latency and duration), and 
depression; these symptoms may occur for up to two years post drug cessation.  The 
symptoms of PAWS tend to be episodic; for example, symptoms may last for days and 
then disappear before re-expressing at a later date.  Treatment modalities usually involve 
instruction on the use coping techniques such as practicing self-care, relaxation, and 
patience (13).   
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Melatonin (N-acetyl-5-methoxytryptamine) 
Melatonin therapy may be beneficial to those experiencing PAWS.  In the U.S., 
melatonin is readily available as a non-regulated, nutraceutical and used for treating sleep 
disorders.  It is commonly found in doses of 0.5 mg, 1 mg, 3 mg, and 5 mg.  Melatonin 
contributes to regulating the sleep/wake cycle, and its synthesis and release follows a 
diurnal rhythm.  In response to darkness, melatonin is synthesized in and then secreted 
from the pineal gland with peak plasma levels occurring at 02:00 (2 am) (28, 29); 
however, exposure to light attenuates norepinephrine release from sympathetic nerve 
terminals resulting in reduced synthesis of melatonin (30, 31).  Because of variation in 
daily light exposure, seasonal fluctuations exist; for example, during the summer months 
when the day is longer, the duration of action of melatonin will be shorter compared to 
winter months (32).  
The actions of melatonin are through receptor independent (e.g., free radical 
scavenging) and dependent mechanisms (e.g., MT1 or MT2 melatonin receptors).  Upon 
receptor binding, the melatonin/melatonin receptor complex elicits effects on intracellular 
proteins that may ultimately impact gene transcription (32-38).  Melatonin receptors are 
ubiquitously expressed throughout the body including expression in the brain (39, 40).   
Melatonin has very low toxicity with a high margin of safety.  However, adverse 
events have been reported; for example, orally administered melatonin may cause vivid 
dreaming or daytime grogginess, but these events usually dissipate with continued use.  
Other adverse events an individual may experience include drowsiness, headache, 
dizziness, small changes in blood pressure, or nausea.  Research regarding nightly, orally 
administered melatonin has demonstrated the following:  is well tolerated, has no abuse 
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potential, does not induce rebound insomnia or withdrawal symptoms, does not affect 
endogenous melatonin production, does not impact psychomotor, performance, mood, or 
cognitive functions, does not negatively affect hepatic and renal function (14, 21-24). 
Due to its lipophilicity, melatonin readily distributes to most tissues and crosses 
the blood-brain barrier.  In humans, oral bioavailability is about 33% with serum levels 
peaking within one hour.  Melatonin undergoes phase I metabolism in the liver by the 
cytochrome P450 enzyme, CYP1A2, to 6-hydroxymelatonin before phase II metabolism 
by sulfotransferases to 6-sulfatoxymelatonin (αMT6).  Up to 85% of a given dose is 
excreted in the urine (41).  Importantly, melatonin levels are affected by various classes 
of drugs (e.g., psychotropic medications) that induce, inhibit, or act as a substrate of 
CYP1A2 (42). 
Melatonin and mood disorders 
 Levels of melatonin and/or αMT6 
 The noradrenergic system is involved in the production of melatonin as well as in 
the pathophysiology of depression.  Individuals with depression have disruption of the 
nightly rhythm of melatonin whereby the onset of melatonin secretion occurs later in the 
night.  Results of a study of 14 inpatients (7 males and 7 females) with major depression 
at the end of a psychotropic medication-free period (14 matched controls for age, gender, 
season, and hormonal treatment), published by scientists at the Universite de Liege in 
Belgium, revealed a significant delay in the nightly melatonin peak in depressive patients 
suggesting a phase-shifting of melatonin production; however, there were no differences 
in mean level or peak of melatonin.  In the depressive group, urinary levels of αMT6 
were higher in the morning compared to night time levels while the urinary levels of the 
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control group displayed the characteristic lowering from night to morning (43).  The 
degree of depression as well as living in a different hemisphere may impact the secretion 
of melatonin.  In a study of 32 psychotropic medication-free patients (9 males and 23 
females) with major depression (32 matched controls for age and gender) and another 15 
drug-free outpatients (5 males and 10 females) with major depression (matched controls 
for age, gender, body mass index, and season) from São Paulo, Brazil, the following was 
documented, urinary levels of αMT6 during the 24 hour and 6 hour periods were similar 
between depressed and control groups suggesting that alterations in nightly melatonin 
production may occur only in more severe depression and in the northern hemisphere  
(44).     
 Melatonin as a treatment 
 In anxious young individuals, melatonin (0.75 mg, nightly, 10 days) improved 
their emotional state (15).  Studies investigating the effects of melatonin using an 
intermediate-release dosage form on anxiety and depression demonstrated an 
improvement in levels of depression and anxiety.  For example, in a group of healthy 
volunteers, melaxen (melatonin IR, 1.5 mg, 2 weeks) decreased levels of depression and 
anxiety (16).   
Melatonin and sleep disorders – insomnia 
 Levels of melatonin and/or αMT6 
 Individuals suffering from insomnia experience late onset of sleep or early 
morning awakening which may be a result of a shift in the circadian rhythm by either 
delaying or advancing it, respectively.  Individuals with insomnia have alterations in the 
nightly secretion pattern of melatonin.  One of the first studies to investigate the possible 
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alteration in secretion pattern in individuals experiencing difficulties maintaining sleep 
(i.e., experiencing frequent awakenings) was performed by a group at University of 
Gottingen in Germany.  Results of the study revealed that plasma levels of melatonin 
increased earlier in the evening and were lower in the middle of the night compared to 
controls (peak value of 82.5 ± 26.5 pg/ml versus 116.8 ± 13.5 pg/ml, respectively).  
Moreover, the levels of melatonin were the most severely reduced in individuals who 
experienced difficulties for more than five years (peak value 72.1 ± 25.0 pg/ml) (45).   
 Melatonin as a treatment  
 Because of its role in circadian systems, melatonin supplementation has been 
shown to be beneficial for the treatment of sleep dysfunctions.  A meta-analysis 
investigating the effects of exogenously administered melatonin on sleep conducted by 
Brzezinski et al. (2005) determined, that even though the pooled data were 
heterogeneous, melatonin reduced sleep onset latency by 4 to 7.5 minutes, increased 
sleep efficiency (the ratio of total sleep time to time in bed) by 2.2%, and increased total 
sleep duration by 12.8 minutes (46).   Results from a prospective 6 to 12 month open-
label study of 244 community dwelling adults (aged 20 to 80 years) with insomnia (112 
completed study 6 months and the other 96 completed 12 months) demonstrated that 
prolonged-release melatonin (2 mg, nightly, 6 to 12 month followed by a 2 week 
withdrawal) significantly increased the number of nights with sleep quality reported as 
“good” or “very good” compared to before treatment (22).  In the European Union (E.U.), 
Circadin (prolonged-release 2 mg melatonin) was approved in 2007 for short-term 
treatment of primary insomnia in individuals aged 55 and older.  Clinical trials have 
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demonstrated improvements in onset of sleep latency, sleep quality, next day alertness, 
and quality of life (21).   
 However, melatonin has also been shown to improve sleep latency in individuals 
without sleep dysfunctions.  In a group of young healthy volunteers without sleep 
disorders, melatonin (0.3 or 1 mg, nightly) reduced onset of sleep latency as well as 
latency to stage 2 sleep.  Additionally, neither dose altered sleep architecture, the pattern 
of sleep as it changes between sleep stages (14).   
Melatonin and comorbidities 
 Melatonin as a treatment 
Individuals experiencing major depressive disorder frequently experience sleep 
difficulties.  Antidepressant medications are generally ineffective in combating sleep 
issues, and the addition of benzodiazepines to the medication regimen is not without 
concerns.  Because of its role in circadian systems and its low abuse potential, melatonin 
supplementation may be beneficial for improving sleep in individuals with comorbidities 
such as depression.  Results of those completing a double-blind, placebo-controlled trial 
beginning with 24 outpatients 22 - 65 years of age (19 completed study) demonstrated 
that the 10 individuals with major depressive disorder given slow release melatonin (5 
mg up to 10 mg) along with fluoxetine for four weeks reported significant improvement 
of scores on the Pittsburgh Sleep Quality Index (PSQI) compared to the nine taking 
placebo and fluoxetine.  However, no differences were detected in the rate of 
improvement in depressive symptoms compared to those given fluoxetine plus placebo.  
Of importance, the slow-release melatonin did not increase the onset of fluoxetine (47).  
In an open pilot study, elderly individuals with signs of depression and sleep disturbances 
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as well as those only experiencing sleep disturbances were given melatonin (3 mg, 
nightly, 21 days) and within 2 to 3 days improvements in sleep quality and reduced 
awakenings were demonstrated in those with or without depression (19).  The largest 
RCT at time of publication involved 33 individuals with major depressive disorder where 
15 were given slow release melatonin (6 mg, nightly, 4 weeks).  Findings demonstrated 
significant improvement of subjective but not objective measures of sleep as well as for 
mood; however, results were not specific to melatonin (i.e., placebo effect) (24).  In a 
randomized, double-blind, crossover, placebo-controlled study testing if exogenous 
melatonin can reduce depressive symptoms in individuals with delayed sleep phase 
syndrome (DSPS), individuals with DSPS and depressive symptoms (n = 8) and DSPS 
without depressive symptoms (n = 12) were enrolled.  Interventions were given for four 
weeks with one week washout in between.  Melatonin decreased depression scores as 
assessed by the Epidemiologic Studies Depression Scale (CES-D) and Hamilton 
Depression Scale-17 in both study groups compared to placebo.  Assessment of αMT6 
revealed those with DSPS and depressive symptoms had alterations in melatonin rhythms 
compared to those without depressive symptoms (18). 
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SYSTEMATIC LITERATURE REVIEW 
 Even though melatonin and its analogues have been used in studies of anxiety, 
depression, and insomnia, the purpose of this study was to investigate the effect of 
melatonin upon PAWS among individuals in recovery from chemical dependency.  
Therefore, the specific objectives of this systematic review were: 1.) to identify studies 
that assessed melatonin levels in the blood and/or αMT6 levels in the urine of chemically 
dependent individuals or those who have undergone withdrawal, 2.) to identify studies 
that used melatonin or its analogs as a treatment in chemically dependent individuals or 
those who have undergone withdrawal, and 3.) the use of melatonin to facilitate the 
withdrawal of benzodiazepine administration and/or its effect on health conditions during 
benzodiazepine withdrawal. 
 The literature search was conducted in Pubmed on June 7, 2016 with no time 
restriction (Figure 1).  The search was set to return only studies conducted in humans.  
After the search was performed, the results were further filtered manually by the author 
to exclude meta-analyses, reviews, systematic reviews, studies without an abstract 
available, and published study protocols.  Abstracts written in English language were 
included regardless of original language of respective article.  Articles were included if 
they met criteria as stated in the aforementioned objectives.  The search strategy included 
the following terms: (“Melatonin”[tiab] OR “Melatonin”[OT] OR “Melatonin”[mesh] 
OR “Ramelteon”[tiab] OR “Ramelteon”[OT] OR “6-sulfatoxymelatonin”[tiab]  OR “6-
sulfatoxymelatonin”[OT]) AND (“Chemical Dependency”[tiab] OR “Substance 
abuse”[tiab] OR “Substance use disorder”[tiab] OR “Addiction”[tiab] OR 
“Alcoholism”[tiab] OR “Illicit drug use”[tiab] OR “Drug dependence”[tiab] OR 
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“Substance dependence”[tiab] OR “Alcohol dependent”[tiab] OR “substance 
withdrawal”[tiab] OR “post acute withdrawal”[tiab] OR “Chemical Dependency”[OT] 
OR “Substance abuse”[OT] OR “Substance use disorder”[OT] OR “Addiction”[OT] OR 
“Alcoholism”[OT] OR “Illicit drug use”[OT] OR “Drug dependence”[OT] OR 
“Substance dependence”[OT] OR “Alcohol dependent”[OT] OR “substance 
withdrawal”[OT] OR “post acute withdrawal”[OT] OR “Substance-Related 
Disorders”[Mesh] OR “Behavior, Addictive”[Mesh] OR “Street Drugs”[Mesh]).   
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Figure 1. Schematic representation of methodology used and selection criteria. 
 
 
 
 
 
 
 
 
 
 
106 articles identified through 
database search (Pubmed) 
Articles Excluded: 
30 articles were reviews 
12 studies were without abstract available 
1 studies were published study protocol 
63 studies were reviewed 
Meeting the criteria of the 
objectives, 20 studies were 
included. 
13 studies met Objective #1 
3 studies met Objective #2 
4 studies met Objective #3 
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Melatonin and chemical dependency  
 Objective #1: Levels of melatonin and/or αMT6 
  Substance use disorder    
 Compared to alcohol use disorder (9 articles), the literature review revealed fewer 
articles (4 articles) investigating plasma levels of melatonin and/or its metabolite in 
individuals with substance use disorder demonstrating a necessity for more research.  
Veit and colleagues investigated circadian hormone profiles in 13 cases of 
politoxicomania compared to 10 persons in a good state of health.  Cases were divided up 
into three groups: Group 1: complete abstinence, Group 2: no hard drug intake, and 
Group 3 acute relapse after a prolonged period of abstinence.  Melatonin levels were 
higher in the group of “abstinents” compared to acute relapsive cases (48). 
 As part of a larger study, an exploratory study of 21 adolescents, 14 males and 
seven females, (mean age of 16.3 ± 1.35 yr, range 14 – 19 yr) who experience sleep 
complaints or daytime sleepiness and have completed substance abuse treatment eight 
weeks prior were enrolled.  Participants kept sleep diaries, wore an actiwatch for seven 
days, completed behavioral and psychological measures, and spent one night for dim 
light melatonin onset assessment where salivary samples were collected every 30 minutes 
beginning at 19:30 to 03:30.  Participants demonstrated disordered sleep and older 
adolescents showed later dim light onset.  Considering that adolescents commonly have a 
delayed phase, a substantial number of participants had early dim light onsets.  Overall, 
the authors highlight the following:  the participants have a wide range of dim light onset 
with delays associated with the older adolescents, the onsets were associated with longer 
sleep onset latency, and finally, onsets and shorter phase angles between sleep offset and 
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dim light onset were significantly related to higher severity of substance abuse issues 
(49).       
 A study sought to investigate 24 hour levels of urine αMT6 in 11 opiate-
dependent individuals during opiate withdrawal while undergoing in-patient methadone 
detoxification.  Levels were assessed during methadone stabilization and on Days 6 and 
12 of withdrawal treatment.  Compared to stabilization (i.e., baseline), urine levels were 
significantly higher on Day 6 but not on Day 12.  There existed a correlation between 
withdrawal symptom score severity and urine levels during stabilization and Day 6 (50).   
 In 13 females with heroin addiction (mean age of 31.7 ± 2.4 yr) compared to 17 
healthy females (mean age of 30.0 ± 1.7 yr), levels of plasma melatonin were 
significantly lower at baseline and six months after heroin withdrawal suggesting 
melatonin levels did not fully recover.  In those with heroin addiction, three and six 
months after drug withdrawal, melatonin levels significantly increased compared to 
baseline, but there existed no significant difference between three and six months (51).    
  Alcohol use disorder   
 In healthy men, acute alcohol exposure may not influence nocturnal melatonin 
secretion in contrast to chronic exposure in those with dependency (52).  Alcohol 
dependent individuals experience difficulties with latency and maintenance of sleep that 
may be attributed to phase-shifting and decreased levels of nocturnal melatonin secretion.   
 In a study of 10 male chronic alcoholic individuals before and after two weeks of 
abstinence, urine melatonin levels as collected in two fractions (08:00 – 20:00) and 
(20:00 – 08:00) revealed that 24 hour levels were higher in individuals during alcohol 
intake compared to sex and age-matched controls.  Moreover, higher day fraction levels 
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were detected in these individuals as well as after alcohol withdrawal.  Overall, the ratio 
of night fraction over day fraction approximated “1” during intake and became greater 
than “1” after withdrawal like the controls (53).  
 As an addition to a larger, worldwide, multinational control study sampling 
depressed and abstinent alcohol dependent men and women from Sweden and California, 
urinary melatonin levels were found to be similar between the two control groups as well 
as between the depressed and alcoholic groups.  However, the levels of the depressed and 
alcoholic groups were significantly lower than the control groups (54).      
 The 24 hour, day- and nighttime melatonin levels were assessed in 10 alcohol 
dependent men during active drinking and two weeks after withdrawal.  Results revealed 
increased daytime levels of urine melatonin and the inversion of the ratio between night- 
and daytime levels during active drinking that normalized upon withdrawal (55).   
 A study of 24 hour plasma levels of melatonin in eight chronic alcohol dependent 
males in a detoxification program and eight healthy controls, levels were assessed on the 
first day of alcohol withdrawal and after 14 days.  The mean 24 hour levels were higher 
during acute withdrawal compared to after 14 days of abstinence and those of the healthy 
controls.  Significance could not be determined due to larger inter-individual differences.  
Based on cosinor analysis, there existed a loss of circadian periodicity in the acute phase 
but periodicity was significantly restored after 14 days (56). 
 Research regarding ten chronically alcohol dependent individuals (mean 11.7 year 
alcohol use with range 2 to 30 year, mean 219 g alcohol daily with range from 60 g to 
360 g, and mean age 47.3 years with range 33 to 64 years), nighttime levels of blood 
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melatonin were disrupted where more than 50% had low secretion (<30 pg/mL) during 
the four days of alcohol withdrawal (57).   
 Another study investigated melatonin levels in alcohol dependent individuals with 
or without delirium tremens during and 1 month after withdrawal.  Individuals with 
delirium tremens had disrupted serum levels during withdrawal that normalized after 
withdrawal; however, those without delirium tremens had normal rhythm during and after 
withdrawal (58).  
 In the absence of major pre-existing or concomitant psychiatric disorders, 11 
alcohol dependent individuals, who underwent withdrawal 14 days prior, had sampling of 
blood melatonin performed every 30 minutes beginning at 22:00 to 06:30.  Results 
revealed that levels were lower during the early part of the night as well as a delay in the 
onset of the plateau or peak value compared to controls with the delay correlating with 
the prolonged sleep latency as determined by polysomnography (20).   
 A study investigated the inversion of melatonin circadian rhythm in seven alcohol 
dependent individuals during acute withdrawal (along with benzodiazepines) and 15 days 
later (without psychotropic medications).  Results demonstrated that in over half the 
individuals the levels of urine αMT6 showed that the inversion of melatonin rhythm 
persisted during acute withdrawal and continued to persist at 15 days in three individuals 
(59).   
 Research investigating dim light melatonin onset in 52 abstinent alcohol 
dependent individuals compared to 19 age- and sex matched healthy controls showed a 
slower rate of rise of levels of salivary melatonin and decreased maximal peak in 
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abstinent individuals.  Specifically focusing on when melatonin levels were increasing, 
there existed a significant delay of 18 minutes in abstinent individuals (60).  
     Objective #2: Melatonin as a treatment 
 In the U.S., melatonin is readily available as a non-regulated, nutraceutical 
commonly used by individuals experiencing sleep disorders such as insomnia.  Because 
of the high abuse potential of hypnotic medications (e.g., benzodiazepines) or issues with 
tolerability and daytime sedation associated with use of sedating psychotropic 
medications, melatonin may be a safer and more appealing treatment option.  Moreover, 
literature shows melatonin may have anxiolytic and antidepressive actions (15, 16, 18, 
24).  However, research is limited as to the effects of melatonin on anxiety, depression, 
and insomnia in individuals in recovery from chemical dependency.     
 Eryshev and collaborators investigated the effects of melaxen in 45 alcohol 
dependent individuals with sleep and mild mood disorders.  Initiated 14 days after 
alcohol withdrawal, melaxen (melatonin IR, 3 to 6 mg, nightly, 3 weeks) decreased the 
mood disorders especially anxiety as assessed with the Hamilton Anxiety Rating Scale 
(HAM-A).  In addition to studying the effects of melaxen on anxiety and depression, self-
reported sleep quality and sleepiness were also assessed with a sleep quality 
questionnaire and the Epworth sleepiness scale, respectively.  Melaxen improved sleep 
onset and duration and quality of sleep as well as decreased daily sleepiness (17). 
 Case series studies have been performed to assess the effects of ramelteon or 
agomelatine, structural analogs of melatonin that act as MT1 and MT2 melatonin receptor 
agonists with agomelatine also acting as a 5-hydroxytryptamine2c antagonist, in alcohol 
dependent individuals with insomnia in the absence of other psychiatric disorders except 
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nicotine dependence.  Both studies were limited by a small sample size and an absence of 
a placebo group.  Ramelteon (8 mg, nightly, 4 weeks) was taken by four females and one 
male, ages 32 - 53 years with alcohol dependency.  Abstinence was initiated in the past 2 
- 13 weeks.  Remelteon improved insomnia scores on the Insomnia Severity Index (ISI), 
reduced onset of sleep latency by about 0.5 hour, and increased total sleep time by more 
than 1 hour (61).    
 Agomelatine (25 mg to 50 mg, nightly, 6 weeks) was investigated in abstinent 
eight males and one female, mean age of 47.2 ± 11.2 years, with mean alcohol 
dependency of 20 ± 8.3 years.  Several individuals were weaned off their sleep-
promoting substances; however disulfram treatment was maintained.  After six weeks of 
treatment, global sleep quality scores obtained from the PSQI significantly decreased 
(62).      
 Objective #3: Melatonin use in benzodiazepine withdrawal 
 Following an extensive literature review, four articles revealed mixed results for 
use of melatonin to facilitate benzodiazepine withdrawal.  In an RCT of 34 older 
individuals (9 men, 25 women, mean 68 ± 13 yr) who were undergoing benzodiazepine 
treatment for six months, melatonin (2 mg controlled release: Circadin) or placebo was 
administered nightly for six weeks.  Individuals were directed to reduce their dosage of 
medications by 50% during week 2, 75% during weeks 3 and 4, and then to discontinue 
completely.  By the end of the study, 14 of 18 (77%) individuals in the melatonin group 
discontinued medications compared to 4 of 16 (25%) in the placebo group.  Sleep quality 
scores were significantly increased in the melatonin group compared to placebo group 
indicating an improvement in sleep quality.  When melatonin was administered to 
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individuals in the placebo group, six more discontinued their benzodiazepine usage.  At 6 
month follow-up, 19 (79%) of those who discontinued usage of benzodiazepines and  
who continued using melatonin remained abstinent and had a significantly improved 
sleep quality compared to baseline scores (63).     
 A randomized, double-blind, placebo-controlled, cross-over control study of 80 
individuals enrolled at a community methadone maintenance clinic was performed to 
investigate the effect of melatonin in reducing sleep difficulties during benzodiazepine 
withdrawal.  Melatonin (5 mg/day) or placebo was administered for 6 weeks with a 1 
week washout before cross-over for another 6 weeks.  Results revealed that the 
discontinuation rate of those 61 individuals who completed the six weeks of treatment 
was similar.  In those that continued using benzodiazepines, sleep quality as measured by 
the PSQI improved in those who took melatonin first compared to those who took 
placebo first; however, no difference was found between groups in those who ceased 
usage (64). 
  A randomized, double-blind, placebo-controlled, cross-over study was conducted 
investigating the effect of melatonin on behavioral disorders and sleep in 22 individuals 
(7 men, 15 women over 65 years of age) and the facilitation of hypnotic medication 
cessation in 14 of those individuals with melatonin (5 mg/day) or placebo being 
administered for two months.  Sleep disorders were measured with the Northside 
Hospital Sleep Medicine Institute (NHSMI) and behavioral disorders with Yesavage 
Geriatric Depression Scale (GDS) and Goldberg Anxiety Scale (GAS).  Melatonin 
improved sleep quality scores compared to baseline and placebo and improved the scores 
 30 
of behavioral disorders assessed.  During melatonin treatment, hypnotic medication 
cessation occurred in nine out of 14 individuals (65).               
 An RCT investigated the efficacy of melatonin as an adjuvant in sedative 
withdrawal in 92 men and women, over 55 years of age presenting with primary 
insomnia and long-term sedative usage.  Melatonin (controlled release, 2 mg) or placebo 
were administered during the 1 month withdrawal along with psychosocial support.  
After 1 month, the reduction of sedative use was similar between groups.  At the 6 month 
follow-up, similar numbers of individuals remained abstinent (n = 14 melatonin and n = 
20 placebo), but the doses of those still using were significantly higher in the melatonin 
group compared to placebo.  These findings suggest that melatonin provided no benefit 
compared to placebo when attempting to withdraw from sedative use (66).     
Summary of literature review 
 As stated previously, melatonin levels begin to rise during the hours of darkness. 
In individual with depression, the onset of nightly melatonin secretion occurs later which 
may be related to severity of depression.  The evidence suggests, however limited, that 
nightly administration of melatonin provides a benefit in individuals experiencing mood 
disorders such as depression and anxiety.  Investigations into melatonin secretion in those 
suffering from insomnia reveal alterations in the nightly secretion of melatonin.  Of 
interest, one of the first studies to investigate the possible alteration in secretion pattern in 
individuals experiencing difficulties maintaining sleep (i.e., experiencing frequent 
awakenings) found plasma levels of melatonin increased earlier in the evening and were 
lower in the middle of the night compared to controls.  Moreover, levels of melatonin 
were the most severely reduced in individuals who experienced sleep difficulties for more 
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than five years.  A meta-analysis investigating the effects of exogenously administered 
melatonin on sleep determined that melatonin reduced sleep onset latency by 4 to 7.5 
minutes, increased sleep efficiency (the ratio of total sleep time to time in bed) by 2.2%, 
and increased total sleep duration by 12.8 minutes.  When focusing on those individuals 
experiencing major depressive disorder with sleep difficulties, research also suggests that 
melatonin may be beneficial for improving sleep in individuals with comorbidities such 
as depression.  Collectively, these findings provide evidence of the effectiveness of 
melatonin administration in those dealing with depression, anxiety, insomnia, or with 
comorbidities of insomnia and depression.  Even though the research was conducted in 
those individuals not in recovery from illicit or non-illicit drug use, these findings provide 
a rationale for investigating its effects in individuals in recovery from illicit drug and 
alcohol use.        
 Individuals in recovery have a high prevalence of mental health symptoms along 
with substance abuse history.  Also, sleep complaints and how their difficulties with sleep 
impact their daily life are common and a cause of concern.  After drug detoxification, the 
individual will experience psychological and emotional symptoms (i.e., PAWS).  The 
symptoms include, but are not limited to, anxiety, sleep disturbances, and depression; 
these symptoms may occur for up to two years post drug cessation and tend to be 
episodic.  These individuals also have multiple prescription medication use including 
psychotropic medications such as antidepressants that are generally ineffective in treating 
sleep issues.  Because of the high abuse potential of hypnotic medications (e.g., 
benzodiazepines) or issues with tolerability and daytime sedation associated with use of 
sedating psychotropic medications (e.g., trazadone and quetiapine), melatonin may be a 
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safer and more appealing treatment option.  Thus, melatonin administration may be 
beneficial to those experiencing PAWS.  In the U.S., melatonin is readily available as a 
non-regulated, nutraceutical and commonly used for treating sleep disorders because 
melatonin contributes to regulating the sleep/wake cycle.  Melatonin has very low 
toxicity with a high margin of safety and research regarding its use has demonstrated the 
following:  it is well tolerated; has no abuse potential; does not induce rebound insomnia 
or withdrawal symptoms; does not affect endogenous melatonin production; does not 
impact psychomotor, performance, mood, or cognitive functions; and does not negatively 
affect hepatic and renal function.  These are important concerns when considering 
administering melatonin to individuals in recovery.   
 The purpose of this study was to investigate the effect of melatonin upon post-
acute withdrawal among males in recovery from chemical dependency.  Therefore, three 
specific objectives were formulated before conducting the systematic review:  1.) to 
identify studies that assessed melatonin levels in the blood and/or αMT6 levels in the 
urine of chemically dependent individuals or those who have undergone withdrawal, 2.) 
to identify studies that used melatonin or its analogs as a treatment in chemically 
dependent individuals or those who have undergone withdrawal, and 3.) the use of 
melatonin to facilitate the withdrawal of benzodiazepine administration and/or its effect 
on health conditions during benzodiazepine withdrawal.  The systematic literature review 
uncovered 20 articles relating to the three objectives.  The majority of articles explored 
melatonin levels in the blood and/or αMT6 levels in the urine of individuals during or 
after withdrawal from alcohol (9 articles) or other substance use (4 articles).  The 
consensus of literature provides evidence that in abstinent alcohol dependent individuals, 
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nightly melatonin secretion tends to be phase-shifted (i.e., delayed) with decreased 
nocturnal levels suggesting that temporal disruption and magnitude of melatonin 
secretion may explain why alcohol dependent individuals experience difficulties with 
latency and maintenance of sleep.        
  Only three and four articles met the criteria for Objective #2 and #3, respectively.   
Based on the review, there seems to be a paucity of studies investigating the use of 
melatonin as a treatment in this population.  Even though the case series studies involving 
melatonin analogues revealed improvements in sleep in abstinent alcohol dependent 
individuals with insomnia in the absence of other psychiatric disorders, these studies 
were limited by a small sample size and an absence of a placebo group.   Regarding 
Objective #3, the literature revealed mixed results for use of melatonin to facilitate 
benzodiazepine withdrawal.  Overall, research is limited as to the effects of melatonin on 
anxiety, depression, and insomnia in individuals in recovery from chemical dependency. 
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METHODS 
Drugs  
 Melatonin [73-31-4] (#5250)  
Trial design 
Full board approval was obtained from the Institutional Review Board at 
Duquesne University and then registered as a clinical trial on Clinicaltrial.gov (Identifier: 
NCT02431728, Received: April 28, 2015) prior to the study implementation.  The trial 
was a single-center, randomized, double-blind, placebo-controlled, parallel-group trial 
conducted in males 18 years of age and older who are in a residential treatment program 
for chemical dependency at the Salvation Army Harbor Light Center (865 West North 
Avenue, Pittsburgh, Pennsylvania, 15233) in the U.S.  Convenience sampling was used to 
recruit individuals from July 2015 to December 2015.  A total sample of 70 participants 
were enrolled and block randomized with an allocation ratio of 1:1 for the interventions, 
5 mg melatonin and placebo.  Financial compensation of $5.00 U.S. was initiated at Day 
7 and continued at each follow-up (Day 14, Day 21 & Day 28).  Intention-to-treat and 
complete case analyses were performed; however, no interim analysis was performed to 
assess efficacy.  Participants completed study materials in a designated room at the 
center.  
Briefly, this study involved the completion of four validated surveys assessing 
self-reported severity of anxiety (Generalized Anxiety Disorder Scale; GAD-7), 
depression (Personal Health Questionnaire Depression Scale; PHQ-8), stress (Perceived 
Stress Scale; PSS-14), and sleep complaints and how is sleep affecting daily life 
(Pittsburgh Sleep Symptom Questionnaire – Insomnia; PSSQ-1) at five time points 
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(Baseline, Day 7, Day 14, Day 21, and Day 28).  At enrollment, an individual expressing 
interest was provided with an informed consent form by the investigator (CDB) and was 
instructed to read the consent form prior to the investigator (CDB) verbally reviewing the 
contents of the form.  At this time, questions were addressed, if any.  It was paramount 
that informed consent was obtained through the willingness of the individual and not 
through a perception of coercion.  The investigator stressed that participation was 
voluntary, would not involve any foreseeable financial costs, and lack of participation 
would not affect their treatment or status at the center.  Furthermore, it was stressed that 
the participant can withdraw at any time; however, the data collected will be used.   
Upon providing informed consent, a business-sized card labeled with the study 
identification number was provided.  If needed, this card will be presented at the weekly 
follow-ups in order to obtain his opaque manilla envelope, labeled with his unique study 
identification number, containing the four self-report surveys and financial compensation. 
After informed consent, the participant completed the health history form containing 
questions addressing social, medical, medication, preventive, mental health, chemical 
dependency, and melatonin histories.  The participant proceeded to complete the four 
self-report surveys, GAD-7, PHQ-8, PSS-14, and PSSQ-1.  If the participant had 
requested help, the investigator (CDB) read the survey question/s, and then provided an 
interpretation of what the question/s was/were asking, if needed.  Upon completion, all 
forms were enclosed in the manilla envelope by the participant, and then placed into a 
secured container by the investigator (CDB).  The study intervention (a capsule card 
containing either 5 mg melatonin and Avicel® or the placebo containing only Avicel®) 
was provided along with specific instructions to administer one capsule by mouth at 
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bedtime (center “lights out” at 24:00) for 28 days.  If a dose was missed, the capsule was 
to remain sealed in the card.  The investigator (CDB) stressed that it was imperative to 
maintain adherence to current pharmacotherapies as prescribed.  To address any adverse 
events relating to the interventions, the participant was encouraged to report any adverse 
events to the investigator (CDB).  The participant was also encouraged at the weekly 
follow-ups to report if any new symptoms were experienced during the past week other 
than those experienced at time of study entrance.  All adverse events were documented.  
At the conclusion of each weekly follow-up, willingness to remain in the study was 
verbally assessed.  Those participants who completed the 28-day study were prompted to 
answer the question, “Do you believe you were taking melatonin – Yes or No?”  To 
protect the anonymity and confidentiality of the participants, all paperwork were de-
identified but contained the unique identification number.  All data containing materials 
were secured in the office of the investigator (CDB) at Duquesne University.  Only the 
principle investigator (VJG) and the co-investigators (CDB & PWE) had access to the 
data.  Dr. Adam Gordon, the physician on record at the center, was aware of the study.     
Participants 
 Eligible participants were males 18 years of age and older who had a recent 
history of chemical dependency and also have co-occurring mental health diagnosis, 
medical conditions, legal system involvement, and/or a history of homelessness.  Study 
inclusion criteria were residence at the Harbor Light Center, willingness to participate in 
the 28-day study, willingness to provide social, medical, medication, preventive, mental 
health, chemical dependency, and melatonin histories, willingness to complete self-
assessments of severity of anxiety, depression, stress, and sleep complaints and how sleep 
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is affecting daily life, willingness to administer daily at bedtime the intervention, and the 
ability to read and speak English.  Participants were excluded if currently self-
administering melatonin or had an adverse history with melatonin supplementation.   
Recruitment 
Recruitment was conducted via study flyers displayed at the center, counselors 
notifying residents, residents notifying residents, investigator (CDB) notifying residents 
twice a week before one of their therapy sessions, and investigator (CDB) having 
discussions with interested resident/s.   
Settings and locations  
The study was conducted at the Salvation Army Harbor Light Center (865 West 
North Avenue, Pittsburgh, Pennsylvania, 15233).  Pittsburgh is a major city located in 
Allegheny County with a population of 300,000 and 1,230,000, respectively (67).  From 
2005 to 2010, the metropolitan statistical area (MSA), counties of Allegheny, Armstrong, 
Beaver, Butler, Fayette, and Washington, consists of 2.1 million persons aged 12 or older 
with 1.9 million being adults aged 18 or older.  According to the NSDUH Report: 
Substance Use and Mental Disorders in the Pittsburgh MSA, an estimated annual mean of 
281,000 persons aged 12 or older (13.4%) used an illicit drug and about 182,000 persons 
aged 12 or older (8.7%) had a substance use disorder in the past year.  Also, an estimated 
116,000 adults aged 18 or older (6.1%) experienced a major depressive episode in the 
past year.  These rates were similar to rates of the State and nation (68).   
The Harbor Light Center is a Pennsylvania Department of Drug & Alcohol 
Program (DDAP) licensed, medically-monitored long-term (3-month), and residential 
substance abuse rehabilitation program for men.  It is a 40-bed, residential treatment 
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program for men 18 years of age and older who have a recent history of chemical 
dependency along with co-occurring mental health diagnosis, medical conditions, legal 
system involvement, and/or a history of homelessness.  Requirements for program entry 
are residency in Allegheny County and possessing a valid Pennsylvania state 
identification.  Residents follow a daily schedule that includes therapy sessions and three 
meals.  The program is aimed to individuals with varying degrees of dependency, and the 
facility is a place where men are cared for physically, mentally, and spiritually in order to 
allow each man to realize his worth, value, and personhood.  Services provided include 
group therapy that incorporates relapse prevention, gratitude, life skills, psychiatric 
medication evaluation, and rational emotive and mental health therapies.  Additionally, 
individual therapy, assignment to an Allegheny County D&A case manager to assist with 
housing and other community-based resources, and meetings with Office of Vocational 
Rehabilitation counselor to aid with educational resources and work are offered.  MAT is 
not provided. 
Interventions 
Participants were randomly assigned to receive capsules containing either 5 mg 
melatonin plus Avicel® filler or the placebo containing only Avicel®.  Avicel® is a 
microcrystalline cellulose powder commonly used by the pharmaceutical industry.  All 
study capsules were compounded by Jeffreys Drug Store (1 North Central Avenue, Ste. 
#1, Canonsburg, PA, 15317).  The capsules were packaged in non-child resistant, foil-
backed cards delivering a 30-day supply (Washington Medical Equipment).  A number 
from 1 to 30 appeared next to each foil-backed capsule corresponding to the day in the 
study.  Even though the study was for 28 days, two extra capsules were provided in case 
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of quality, loss, or sanitary issues were encountered.  Capsules were clear, matched for 
size, and the formulation within appeared as a white, microcrystalline powder.  Melatonin 
and Avicel® are tasteless.  Capsule content was independently confirmed by the 
laboratory of Kevin J. Tidgewell, Ph.D. (Assistant Professor of Medicinal Chemistry, 
Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA) 
using high performance liquid chromatography (See Appendix).    
Outcomes 
 The primary outcome measures were to determine the effect of melatonin or 
placebo along with current treatment regimen on the change in severity of: 1.) anxiety as 
measured by the GAD-7, 2.) depression as measured by the PHQ-8, 3.) stress as 
measured by the PSS-14, and 4.) sleep complaints and how sleep is affecting daily life as 
measured by the PSSQ-1.  Surveys were completed at five different time points 
(Baseline, Day 7, Day 14, Day 21, and Day 28).  Also, the change from Baseline and Day 
28 was determined by a response of an improvement of 50% or higher in the survey 
scores for each scale.  Secondary outcome measures were to acquire participant histories 
(social, medical, medication, preventive, mental health, chemical dependency, and 
melatonin use), determine any adverse events through self-report, and determine 
adherence to study interventions.  
Instruments  
Evaluation methods utilized structured, self-reported surveys:  GAD-7, PHQ-8, 
PSS-14, and PSSQ-1.  An investigator generated form was used to collect social, 
medical, medication, preventive, mental health, chemical dependency, and melatonin 
histories.  Importantly, each designated time frame as indicated on the surveys was used 
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to assess baseline measures; then, each time frame was changed to “over the last seven 
days” for the other follow-up times.  For the PSSQ-1, mean scores of each subscale were 
determined, and the scale was not used to assign a diagnosis of insomnia disorder.  
The GAD-7 measures self-reported severity of anxiety.  It is a 7-item scale 
assessing severity as measured by a symptom checklist over the last two weeks.  It 
employs a 4-point scale with the response options of “Not at all” (0 pts), “Several days” 
(1 pt), “More than half the days” (2 pts), and “Nearly every day” (3 pts).  Severity is 
based on the sum total where 15 - 21 is considered “severe anxiety (69).”   
 The PHQ-8 measures self-reported degree of depression.  It is an 8-item scale 
assessing degree as measured by a symptom checklist over the last two weeks.  It 
employs a 4-point scale with the response options of “Not at all” (0 pts), “Several days” 
(1 pt), “More than half the days” (2 pts), and “Nearly every day” (3 pts).  The higher the 
sum total the greater the degree of depression; for example, a score of 20 or more is 
considered severe major depression (70). 
 The PSS-14 measures self-reported degree of stress.  It is a 14-item scale 
assessing degree as measured by a checklist of the individual’s thoughts and feelings 
during the past month.  It employs a 5-point scale with the response options of “Never” 
(0 pts), “Almost Never” (1 pt), “Sometimes” (2 pts), “Fairly Often” (3 pts), and “Very 
Often” (4 pts).  Because some questions are positively stated, scores are obtained by 
reversing the scoring on items 4, 5, 6, 7, 9, 10, and 13, for example a score of “4” 
becomes a score of “0”.  The scores are summed with higher score indicating more 
perceived stress (71). 
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 The PSSQ-1 measures self-reported severity of sleep complaints and how sleep 
affects daily life.  It is a 13-item scale that assesses severity during the past month with 
two subscales: Sleep complaints (Questions 1-5) and how sleep is affecting daily life 
(Questions 6-13).  Sleep complaints are assessed by a 6-point scale with the response 
options of “Never” (0 pts), “Do not know” (1 pt), “Rarely” (2 pts), “Sometimes” (3 pts), 
“Frequently” (4 pts), and “Always” (5 pts) and asks “How long has the symptom lasted.”  
To assess for how sleep is affecting daily life, it employs a five point scale with the 
response options “Not at all” (0 pts), “A little bit” (1 pt), “Moderately” (2 pts), “Quite a 
bit” (3 pts), and “Extremely” (4 pts) (72).  Mean scores for each subscale were 
determined.   
Sample size 
 The study involved repeated measures (Baseline, Day 7, Day 14, Day 21, Day 
28), within-between (Intervention by Time) research design.  The independent variables 
were intervention (melatonin and placebo) and time (Baseline, Day 7, Day 14, Day 21, 
and Day 28).  The dependent variable was mean self-reported score.  G*power 3.1.9 was 
used to perform a power analysis for ANOVA: Repeated measures, within-between 
interaction.  Statistical power (1 - βerror probability) of 0.80 with a small effect size of 
0.15 was selected.  The Type 1 error (α) probability was 0.05.  Based on the analysis 
(total sample size = 56) and adjusted to account for predicted loss to follow-up of <20%, 
a total of 70 individuals were enrolled.   
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Randomization 
To ensure equal treatment allocation of 1:1, block randomization with a block size 
of four and a scheme of AABB, BBAA, ABAB, BABA, ABBA, and BAAB (sequence 
repeated) was used to randomize all 70 participants (73).   
Allocation concealment mechanism and implementation 
 The consent form, health history form, surveys, financial compensation envelope, 
capsule card labeled with a study ID number, and study identification card (business 
sized card with ID number) were contained in, according to allocation sequence, 
sequentially numbered (1-70), opaque manilla envelopes individually secured by a metal 
clasp.  Allocation concealment (e.g., preparing envelopes) was performed by a student 
volunteer from the Mylan School of Pharmacy at Duquesne University.  Implementation 
procedures were performed by investigator (CDB).  After receiving informed consent, the 
manilla envelope was opened revealing the study identification card, and then the study 
identification number was placed on the front of the envelope.   
Blinding/Masking 
Study interventions (i.e., capsule cards) were provided by the manufacturer to the 
principal investigator (VJG) in two boxes labeled “A” and “B.”  Sealed envelopes 
containing the key were provided by the pharmacy.  One sealed envelope was maintained 
in a secured location in the office of the principle investigator (VJG) and another sealed 
envelope was provided to the center director (SL).  A sealed envelope was provided to 
the center director for safety purposes (e.g., hospitalization of participant).  According to 
allocation sequence, capsule cards were then labeled on the back in the lower right-hand 
corner with the study identification number.  Another set of sealed envelopes were 
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generated enclosing the key for this scheme.  These envelopes were also provided to and 
maintained by the principle investigator (VJG) and the center director (SL).  The overall 
randomization key, linking box letter to study identification number, was maintained as 
an electronic file on the computer of the investigator (CDB).  The investigators and 
participants were blind to intervention allocation.  Participants were also unaware of the 
exact intervention received.  Upon completion of the last participant completing the last 
survey day, the study was unmasked to the investigators (VJG, CDB, & PWE) by 
comparing the randomization key to the contents of both unsealed envelopes. 
Statistical methods 
 No interim analysis was performed to assess efficacy.  Data obtained from the 
health histories were tallied and reported as percentages, as warranted.  To determine if 
significant differences exist in the data obtained from the health histories between the two 
groups, Fisher’s exact, Chi-square, or unpaired t-tests (two-tailed) were performed.  The 
study involved a repeated measures (Baseline, Day 7, Day 14, Day 21, Day 28), within-
between (Intervention by Time) research design.  Intention-to-treat analysis, in which all 
participants were analyzed in the group to which they were assigned, and complete case 
analysis, in which all participants who completed the 28 day study, were performed.  To 
analyze the data obtained from those fulfilling the intention-to-treat and complete case 
criteria, a two-way ANOVA (Intervention by Time, two-tailed) followed by a Tukey’s 
multiple comparison test was performed.     
The change from Baseline to Day 28 of each participant was dichotomized as 
either a response or no response.  Response was defined as improvement of 50% or 
greater in the survey scores (GAD-7, PHQ-8, PSS-14, and PSSQ-1) from Baseline to Day 
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28.  For those lost to follow-up, the participants were assumed to have no response (i.e., 
assumed worst case).  The proportion of response/no response were compared across 
groups with contingency table analysis by performing a Fisher’s exact test (two-tailed, CI 
95%).  Strength of association were reported as relative risk (95% CI).  GraphPad Prism 
6 software (GraphPad Software Inc., La Jolla, CA) was used to perform the statistical 
analyses.  Significance level was α = 0.05 (CI 95%) for all tests.  Significance, if any, 
was defined as p ≤ 0.05, p ≤ 0.01, p ≤ 0.001, and p ≤ 0.0001 as indicated by (*), (**), 
(***), and (****), respectively.   
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RESULTS 
Participant recruitment, allocation, follow-up, and analysis 
From July 2015 to December 2015, 70 potential participants were randomized to 
either the experimental group (Melatonin, n = 35) or the comparison group (Placebo, n = 
35).  It was revealed at Day 21 that one participant was not taking the intervention (i.e., 
placebo), and the data was excluded except for baseline.  Intention-to-treat and complete 
case analyses were performed.   
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Assessed eligibility, n = 70 
 
Randomized, n = 70 
 
 
Allocated to melatonin                                                       Allocated to placebo 
(experimental group),                                                         (comparison group)   
n = 35                                                                                  n = 35 
Received allocated intervention,                                        Received allocated intervention 
n = 35                                                                                  n = 35 
 
 
Attended follow-up                                                            Attended follow-up 
Day 7, n = 32                                                                      Day 7, n = 32 
Day 14, n = 30                                                                    Day 14, n = 31 
Day 21, n = 26                                                                    Day 21, n = 26 
Day 28, n = 24                                                                    Day 28, n = 24 
 
Analyzed                                                                            Analyzed 
Intention-to-treat, n = 35                                                    Intention-to-treat, n = 35 
Complete case, n = 24                                      *One participant not taking intervention  
                   Complete case, n = 24                                                                                                                                                                                
                                                                                            
 
 
Figure 2. Flow diagram for participant recruitment, allocation, follow-up, and analysis. 
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Reasons for loss to follow-up 
 Table 1 presents the reasons and percent of loss to follow-up.  The study retained 
68.6% of the participants (a loss to follow-up of 31.4%), and was similar between the two 
groups.  The most prevalent reason was non-illicit or illicit drug relapse.  These 
participants were detected at the center to be under the influence of alcohol (n = 2), 
benzodiazepines (n = 2), heroin (n = 3), or opiates (n = 3).  Because of administrative rule 
violations, four participants had to leave the center.  Two participants withdrew due to 
adverse events of tiredness (melatonin) and diarrhea (placebo).  One individual withdrew 
immediately after completing surveys at baseline (placebo).  One death by possible drug 
overdose was recorded.  This participant was allowed to leave the center for the weekend 
and was found deceased on a city street.  Statistical analysis revealed no significant 
differences between the two groups for loss to follow-up. 
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Table 1    
Loss to Follow-up       
Variable Total Melatonin Placebo 
n 70 35 35 
Loss to Follow-up, n (%)    
Baseline 0 (0.0) 0 (0.0) 0 (0.0) 
D7 6 (8.6) 3 (8.6) 3 (8.6) 
D14 9 (12.9) 5 (14.2) 4 (11.4) 
D21 18 (25.7) 9 (25.7) 9 (25.7) 
D28 22 (31.4) 11 (31.4) 11 (31.4) 
Reasons, n (%, % yes) 22 (31.4) 11 (15.7) 11 (15.7) 
Adverse Event 2 (2.9, 9.1) 1 (2.9, 9.1) 1 (2.9, 9.1) 
Adherence w/ Intervention 1 (1.4, 4.5) 0 (0.0, 0.0) 1 (2.9, 9.1) 
Administrative 4 (5.7, 18.2) 1 (2.9, 9.1) 3 (8.6, 27.3) 
Death (drug overdose) 1 (1.4, 4.5) 1 (2.9, 9.1) 0 (0.0, 0.0) 
Relapse 10 (14.3, 45.5) 5 (14.3, 45.5) 5 (14.3, 45.5) 
Withdrew 2 (2.9, 9.1) 1 (2.9, 9.1) 1 (2.9, 9.1) 
Work 1 (1.4, 4.5) 1 (2.9, 9.1) 0 (0.0, 0.0) 
Unknown 1 (1.4, 4.5) 1 (2.9, 9.1) 0 (0.0, 0.0) 
    
% yes is defined as the number of those lost to follow-up for a specific reason  
divided by the total number lost to follow-up multiplied by 100.  
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Baseline self-reported social and current medication histories 
Table 2 presents the self-reported social and current medication histories at 
baseline.  The sample had a mean age of 40.4 ± 11 years (range of 21 – 65 and median 
39), and consisted mostly of participants who identified as white (70%), single (74.3%), 
and with an education level of high school/G.E.D. or less (77.1%).  Age was not reported 
by two participants in the Melatonin group and one participant in the Placebo group.  
Sixty-five participant (92.9%) reported currently taking prescribed medications (i.e., 
those medications expected to be taken during the 28-day study).  The mean number of 
medications prescribed was 3.5 ± 2.2 (range of 0 - 11, median 3, and mode 3).  There 
were 75 different prescribed pharmacotherapies including nutraceuticals for a total of 242 
with most medications being used for treating conditions of the central nervous and 
cardiovascular systems.  If all nutraceuticals (e.g., vitamins, minerals, and supplements), 
except for folic acid (vitamin B9) because of its use in treating anemia as well as folate 
deficiency associated with alcoholism and liver disease, were excluded, there remained 
70 different pharmacotherapies accounting for 231 total medications (Data not shown).  
One participant reported antivirals for HIV/AIDS.  Statistical analyses revealed no 
significant differences between the two groups for age, race, marital status, education, 
medication history, or mean number of medications prescribed.  
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Table 2    
Self-reported Social and Current Medication Histories at Baseline 
Variable Total Melatonin Placebo 
n 70 35 35 
Age, years    
Mean, SD* 40.4 ± 11.0 39.5 ± 11.9 41. 3 ± 10.3 
Range 21 - 65 21 - 65 25 - 63 
Median 39 37 41 
Race, n (%)    
White 49 (70.0) 25 (71.4) 24 (68.6) 
Black/African American 17 (24.3) 8 (22.9) 9 (25.7) 
Other 4 (5.7) 2 (3.2) 2 (3.2) 
Marital Status, n (%)    
Single 52 (74.3) 26 (74.3) 29 (74.3) 
Divorced 14 (20) 5 (14.3) 9 (25.7) 
Other 4 (5.7) 4 (11.4) 0 (0.0) 
Education, n (%)    
High School/G.E.D. or less 54 (77.1) 30 (85.7) 24 (68.6) 
Technical School 3 (4.3) 1 (2.9) 2 (5.7) 
College (attended or completed) 13 (18.6) 4 (11.4) 9 (25.7) 
Medication History, n (%)     
Yes 65 (92.9) 32 (91.4) 33 (94.3) 
Medications     
Mean, SD 3.5 ± 2.2 3.7 ± 2.3 3.2 ± 2.2 
Range 0 - 11 0 - 9  0 - 11 
Median 3 4 3 
Mode, n 3 (15) 5 (7) 3 (10) 
Different Medications, # 75 53 58 
Medications, # 242 129 113 
Antiviral (HIV/AIDS), # (%) 2 (0.8) 0 (0.0) 2 (1.8) 
Cardiovascular, # (%)* 43 (17.8) 29 (22.5) 14 (12.4) 
Central Nervous, # (%) 157 (64.8) 82 (63.6) 75 (66.4) 
Endocrine, # (%) 9 (3.7) 2 (1.5) 7 (6.2) 
Gastrointestinal, # (%) 9 (3.7) 3 (2.3) 6 (5.3) 
Nutraceuticals, # (%)* 11 (4.5) 8 (6.2) 3 (2.7) 
Respiratory, # (%) 1 (0.4) 0 (0.0) 1 (0.9) 
Other, # (%)* 10 (4.1) 5 (3.9) 5 (4.4) 
    
*Age was not reported by two participants in the Melatonin group and by one   
participant in the Placebo group.    
*Nutraceuticals included vitamins, minerals, and supplements; however, 
folic acid (vitamin B9) was included in "Cardiovascular."  NSAIDS were included 
in "Other;" however, aspirin was included in "Cardiovascular."  
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Baseline self-reported medical history 
Table 3 presents the self-reported medical histories identifying the total number 
of conditions reported for each system as well as the most reported condition for each 
system at baseline.  Sixty–two participants (88.6%) reported a medical condition 
diagnosed by a doctor with a mean of 3.0 ± 3.1 (range 0 – 18, median 2, and mode 1).  In 
aggregate, the participants tended to present with histories of high blood pressure, 
heartburn/acid reflux, hepatitis, arthritis, and/or neuromuscular symptoms related to disc 
herniation.  One participant reported a history of HIV/AIDS.  However, the category of 
“Neurological/Psychiatric Events” did not address mental health conditions such as 
anxiety, bipolar, depression, and schizophrenia; these were reserved for the mental health 
history questionnaire (See Table 5).  Statistical analyses revealed no significant 
differences between the two groups for the mean number of diagnosed medical 
conditions as well as the number of participants reporting conditions for each system.  
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Table 3    
Self-reported Medical History at Baseline      
Variable Total Melatonin Placebo 
n 70 35 35 
Medical History, n (%)    
Yes 62 (88.6) 32 (91.4) 30 (85.7) 
Medical Conditions    
Mean, SD 3.0 ± 3.1 3.6 ± 3.5 2.5 ± 2.4 
Range 0 - 18 0 - 18 0 - 11 
Median 2 3 2 
Mode, n 1 (17) 1 (8) 2 (9) 
Cardiovascular, # 35 24 11 
Yes, n (%) 23 (32.9) 15 (42.9) 8 (22.9) 
High Blood Pressure, n (%, % yes) 20 (28.6, 87.0) 13 (37.1, 86.7) 7 (20.0, 87.5) 
High Cholesterol, n (%, % yes) 7 (10.0, 30.4) 6 (17.1, 40.0) 1 (2.9, 12.5) 
Endocrine, # 9 3 6 
Yes, n (%) 9 (12.9) 3 (8.6) 6 (17.1) 
Diabetes, n (%, % yes) 7 (10.0, 77.8) 2 (5.7, 66.7) 5 (14.3, 83.3) 
Gastrointestinal, # 25 14 11 
Yes, n (%) 23 (32.9) 13 (37.1) 10 (28.6) 
Heartburn/Acid Reflux, n (%, % yes) 18 (25.7, 78.3) 10 (71.4, 76.9) 8 (22.9, 80.0) 
Genitourinary/Renal, # 10 8 2 
Yes, n (%) 7 (10.0) 6 (17.1) 1 (2.9) 
Kidney Stones, n (%, % yes) 4 (5.7, 57.1) 4 (11.4, 66.7) 0 (0.0, 0.0) 
Hepatic/Gall Bladder, # 22 11 11 
Yes, n (%) 18 (25.7) 9 (25.7) 9 (25.7) 
Hepatitis, n (%, % yes) 17 (24.3, 94.4) 9 (25.7, 81.8) 8 (22.9, 88.9) 
Musculoskeletal/Spinal, # 48 29 19 
Yes, n (%) 31 (44.3) 17 (48.6) 14 (40.0) 
Arthritis, n (%, % yes) 10 (14.3, 32.3) 7 (20.0, 41.2) 3 (8.6, 21.4) 
Cervical or Lumbar Disc, n (%, % yes) 12 (17.1, 38.7) 6 (17.1, 35.3) 6 (17.1, 42.9) 
Neck/Back Pain, n (%, % yes) 16 (22.9, 51.6) 9 (25.7, 52.9) 7 (20.0, 50.0) 
Neurological/Psychiatric, # 33 21 12 
Yes, n (%) 19 (27.1) 11 (31.4) 8 (22.9) 
Migraines/Headaches, n (%, % yes) 7 (10.0, 36.8) 5 (14.3, 45.5) 2 (5.7, 25.0) 
Numbness/Tingling, n (%, % yes) 7 (10.0, 36.8) 5 (14.3, 45.5) 2 (5.7, 25.0) 
Respiratory/Ears/Nose/Throat, # 25 12 13 
Yes, n (%) 20 (28.6) 10 (28.6) 10 (28.6) 
Asthma, n (%, % yes) 5 (7.1, 25.0) 2 (5.7, 20.0) 3 (8.6, 30.0) 
Sleep Apnea, n (%, % yes) 6 (8.6, 30.0) 2 (5.7, 20.0) 4 (11.4, 40.0) 
Other, # 6 3 3 
Yes, n (%) 6 (8.6) 3 (8.6) 3 (8.6) 
HIV/AIDS, n (%, % yes) 1 (1.4, 16.7) 1 (2.9, 33.3) 0 (0.0, 0.0) 
    
% yes is defined as the number of those reporting a specific condition divided the total number reporting  
a condition multiplied by 100.    
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Baseline self-reported use of nicotine delivery products, consumption of caffeinated 
beverages, and preferred type of exercise 
Table 4 presents the self-reported use of nicotine delivery products, consumption 
of caffeinated beverages, or preferred type of exercise at baseline.  Sixty-three 
participants (90%) reported use of nicotine delivery products with cigarettes being the 
preferred mode.  The vast majority (94.3%) also consumed caffeinated beverages with 
coffee being preferred.  The participants were physically active with about three quarters 
(72.9%) of them choosing some form of exercise with lifting weights being preferred.  
Statistical analyses revealed no significant differences between the two groups for the use 
of nicotine delivery products, consumption of caffeinated beverages, or preferred type of 
exercise 
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Table 4    
Self-reported Nicotine, Caffeinated Beverages, and Exercise Histories at Baseline 
Variable Total Melatonin Placebo 
n  70 35 35 
Nicotine, n (%, % yes)    
Yes, n (%) 63 (90.0) 32 (91.4) 31 (88.6) 
Chewing tobacco 4 (5.7, 6.3) 2 (5.7, 6.3) 2 (5.7, 6.5) 
Cigarettes 56 (80.0, 88.9) 31 (88.6, 96.9) 25 (71.4, 80.6) 
Snuff 12 (17.1, 19.0) 5 (14.3, 15.6) 7 (20.0, 22.6) 
Vapor 0 (0.0, 0.0) 0 (0.0, 0.0) 0 (0.0, 0.0) 
Caffeinated Beverages, n (%, % yes)    
Yes, n (%) 66 (94.3) 33 (94.3) 33 (94.3) 
Coffee 55 (78.6, 83.3) 26 (74.3, 78.8) 29 (82.9, 87.9) 
Soda 35 (50.0, 53.0) 20 (57.1, 60.6) 15 (42.9, 45.5) 
Tea 21 (30.0, 31.8) 10 (28.6, 30.3) 11 (31.4, 33.3) 
Exercise, n (%, % yes)    
Yes, n (%) 51 (72.9) 24 (68.6) 27 (77.1) 
Weights 36 (51.4, 70.6) 17 (48.6, 70.8) 19 (54.3, 70.4) 
Aerobics/Pilates/Yoga 10 (14.3, 19.6) 2 (5.7, 8.3) 8 (11.4, 29.6) 
Running 9 (12.9, 17.6) 2 (5.7, 8.3) 7 (20.0, 25.9) 
Sports 6 (8.6, 11.8) 2 (5.7, 8.3) 4 (11.4, 14.8) 
Other 16 (22.3, 31.4) 7 (20.0, 29.2) 9 (25.7, 33.3) 
    
% yes is defined as the number of those reporting a specific use divided by the total number 
reporting a use multiplied by 100.    
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Self-reported mental health conditions diagnosed by a medical professional 
 Table 5 presents the self-reported mental health histories at baseline.  Ninety-one 
percent (91.4%) reported a history of mental health conditions with diagnosis obtained 
mostly in a hospital setting (71.9% of those reporting a diagnosis).  On average, 1.9 ± 0.9 
conditions were reported; specifically, 49 participants reported comorbidity of at least 
two conditions accounting for 76.6% of those reporting a mental health history.  Most 
were diagnosed with depression followed by anxiety while 62.5% of those reporting a 
mental health history were comorbid for depression and anxiety with or without other 
mental health conditions.  Statistical analyses revealed no significant differences between 
the two groups for reported mental health history, mean number of conditions, location of 
diagnosis as well as the number of participants diagnosed or comorbid.   
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Table 5    
Self-reported Mental Health History at Baseline     
Variable Total Melatonin Placebo 
n 70 35 35 
Mental Health History, n (%)    
Yes  64 (91.4) 32 (91.4) 32 (91.4) 
Conditions    
Mean, SD 1.9 ± 0.9 1.9 ± 0.9 1.8 ± 0.9 
Median 2 2 2 
Mode, (n) 2 (32) 2 (16) 2 (16) 
Diagnosis, n (%, % yes)    
Anxiety 45 (64.2, 70.3) 26 (74.3, 81.3) 19 (54.3, 59.4) 
Bipolar 24 (34.3, 37.5) 11 (31.4, 34.3) 13 (37.1, 40.6) 
Depression 56 (80.0, 87.5) 27 (77.1, 84.4) 29 (82.9, 90.6) 
Schizophrenia 5 (7.1, 7.8) 2 (5.7, 6.3) 3 (8.6, 9.4) 
Comorbid, n (%, % yes)    
Total (≥2 conditions) 49 (70.0, 76.6) 25 (71.4, 78.1) 24 (68.6, 75.0) 
Depression & Anxiety 40 (57.1, 62.5) 22 (62.9, 68.8) 18 (51.4, 56.3) 
Location, n (%, % yes)    
Hospital 46 (65.7, 71.9) 22 (62.8, 68.8) 24 (68.6, 75.0) 
PCP/Clinic/Rehab Center 12 (17.1, 18.8) 6 (17.1, 18.8) 6 (17.1, 18.8) 
Other 6 (8.6, 9.4) 4 (11.4, 12.5) 2 (5.7, 6.3) 
    
% yes is defined as the number of those reporting a specific diagnosis/location divided by the  
total number reporting a diagnosis/location multiplied by 100.  
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Self-reported illicit and non-illicit drug history at baseline 
 Table 6 presents the self-reported illicit and non-illicit drug histories at baseline.  
On average, 2.5 ± 1.8 drugs (range of 1 -10, median 2, and mode 2).  Alcohol use 
(60.0%) was the most reported followed by heroin (51.4%) and crack cocaine (38.6); 
however, 15.7% reported only using alcohol and 10.0% reported only using heroin.  One 
of the most reported multiple drug use was alcohol and cocaine or crack cocaine (27.1%).  
Another popular usage was heroin and opiate drugs being reported by 20.0% of the 
participants, and 17.1% reported using alcohol and heroin or opiate drugs.  Statistical 
analyses revealed no significant differences between the two groups for the mean number 
of illicit and non-illicit drug used as well as for each illicit and non-illicit drug used.   
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Table 6    
Self-reported Illicit and Non-illicit Drug History     
Variable Total Melatonin Placebo 
n 70 35 35 
Mean, SD 2.5 ± 1.8 2.4 ± 1.8 2.6 ± 1.7 
Range 1 - 10 1 - 10 1 - 10 
Median 2 2 2 
Mode, (n)  2 (29) 2 (15) 2 (14) 
Illicit & Non-illicit Drugs, n (%)    
Alcohol 42 (60.0) 21 (60.0) 21 (60.0) 
Alcohol only 11 (15.7) 7 (20.0) 4 (11.4) 
Alcohol & Cocaine or Crack Cocaine 19 (27.1) 9 (25.7) 10 (28.6) 
Alcohol & Heroin or Opiate Drugs 12 (17.1) 8 (22.9) 4 (11.4) 
Amphetamine 6 (8.6) 3 (8.6) 3 (8.6) 
Benzodiazepines 4 (5.7) 2 (5.7) 2 (5.7) 
Cocaine 16 (22.9) 5 (14.3) 11 (31.4) 
Crack Cocaine 27 (38.6) 12 (34.3) 15 (42.9) 
Cocaine & Crack Cocaine 10 (14.3) 5 (14.3) 5 (14.3) 
Hash 2 (2.9) 1 (2.9) 1 (2.9) 
Heroin 36 (51.4) 20 (57.1) 16 (45.7) 
Heroin only 7 (10.0) 4 (11.4) 3 (8.6) 
Heroin & Opiate Drugs 14 (20.0) 7 (20.0) 7 (20.0) 
LSD 3 (4.3) 1 (2.9) 2 (5.7) 
Marijuana 20 (28.6) 10 (28.6) 10 (28.6) 
Marijuana & Alcohol 14 (20.0) 7 (20.0) 7 (20.0) 
Marijuana & Cocaine or Crack Cocaine 14 (20.0) 6 (17.1) 8 (22.9) 
MDMA 1 (1.4) 1 (2.9) 0 (0.0) 
Opiate Drugs 17 (24.2) 8 (22.9) 9 (25.7) 
PCP 2 (2.9) 1 (2.9) 1 (2.9) 
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Self-reported melatonin history at baseline 
 Table 7 presents the self-reported melatonin history at baseline.  Thirty 
participants (42.9%) reported a history of melatonin use with 100.0% indicating usage for 
sleep.  Most participants obtained the melatonin from a clinician (53.3%) most likely in a 
hospital, rehabilitation center, or provided to them (46.7%).  Only 40.0% could recall the 
dose taken with between 3 to 10 mg being the most popular dose range.  Seventy percent 
of participants who reported a history believed melatonin had an effect.  Most of the 
participants (70.0%) reported a prior usage of greater than one month before study 
enrollment.  Statistical analyses revealed no significant differences between the two 
groups for prior history, reason for use, motivation, place acquired, time of last use, recall 
dose taken, or believed it helped.  
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Table 7    
Self-reported Melatonin History at Baseline     
Variable Total  Melatonin Placebo 
n 70 35 35 
Prior History, n (%)    
Yes 30 (42.9) 17 (48.6) 13 (37.1) 
Reason, n (% yes)     
Sleep 30 (100.0) 17 (100.0) 13 (100.0) 
Motivation, n (% yes)    
Clinician 16 (53.3) 11 (64.7) 5 (38.5) 
Self 11 (36.7) 6 (35.3) 5 (38.5) 
Both  3 (10.0) 0 (0.0) 3 (23.1) 
Acquired, n (% yes)    
Hospital/Rehab Center/Provided 14 (46.7) 8 (47.1) 6 (46.2) 
Pharmacy 5 (16.7) 1 (5.9) 4 (30.8) 
Retail 8 (26.7) 5 (29.4) 3 (23.1) 
Other 1 (3.3) 1 (5.9) 0 (0.0) 
Unknown/No Response 3 (10.0) 2 (11.8) 1 (7.7) 
Last Use, n (% yes)    
< 1 week 1 (3.3) 1 (5.9) 0 (0.0) 
≤ 1 month 7 (23.3) 5 (29.4) 2 (15.4) 
> 1 month to ≤ 1 year  10 (33.3) 6 (35.3) 4 (30.8) 
> 1 year 11 (36.7) 5 (29.4) 6  (46.2) 
Unknown/No Response 1 (3.3) 0 (0.0) 1 (7.7) 
Recall Dose, n (% yes)    
Yes, n (%) 12 (40.0) 9 (52.9) 3 (23.1) 
1 mg 0 (0.0) 0 (0.0) 0 (0.0) 
3 - 10 mg 10 (83.3) 8 (88.9) 2 (66.7) 
>10 mg 2 (16.7) 1 (11.1) 1 (33.3) 
Believe It Helped?, n (% yes)    
Yes 21 (70.0) 11 (64.7) 10 (76.9) 
No  5 (16.7) 4 (23.5) 1 (5.9) 
Unknown/No Response 4 (13.3) 2 (11.8) 2 (15.4) 
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Self-reported belief intervention taken was melatonin 
 Table 8 presents the self-reported belief of those who completed the 28-day study 
that the intervention taken was melatonin.  Twenty-one participants (43.8%) reported a 
history of melatonin use.  Seventeen participants (81.0%) reported that the prior use 
helped.  Interestingly, thirty-four participants (70.8%) believed that the intervention they 
were taking was melatonin while fourteen participants (29.2%) believed it was placebo.  
Fisher’s exact test revealed there was a significant difference in identified taken 
intervention between the groups, p = 0.0084.  Twenty-two participants (45.8%) correctly 
identified the intervention they were provided while 26 participants (54.2%) were 
incorrect.  Moreover, 12 participants (25.0%) who incorrectly identified the provided 
intervention reported a prior history of melatonin.  Statistical analyses revealed no 
significant differences between the two groups for prior history, prior use helped, and 
belief intervention taken was melatonin.   
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Table 8    
Self-reported Belief Intervention taken was Melatonin    
Variable Total  Melatonin Placebo 
n (completed 28 days) 48 24 24 
Prior History, n (%)    
Yes 21 (43.8) 11 (45.8) 10 (41.7) 
No 27 (56.3) 13 (54.2) 14 (58.3) 
Prior Use Helped, n (%)    
Yes 17 (81.0) 8 (72.7) 9 (90.0) 
No  2 (9.5) 2 (18.2) 0 (0.0) 
Unknown/No Response 2 (9.5) 1 (9.1) 1 (10.0) 
Belief Intervention was Melatonin, n (%)    
Yes 34 (70.8) 16 (66.7) 18 (75.0) 
No 14 (29.2) 8 (33.3) 6 (25.0) 
Identified Taken Intervention, n (%) **    
Correct 22 (45.8) 16 (66.7) 6 (25.0) 
Yes Prior History 9 (18.8) 7 (29.2) 2 (8.3) 
No Prior History 13 (27.1) 9 (37.5) 4 (16.7) 
Incorrect 26 (54.2) 8 (33.3) 18 (75.0) 
Yes Prior History 12 (25.0) 4 (16.7) 8 (33.3) 
No Prior History 14 (29.2) 4 (16.7) 10 (41.7) 
    
Asterisks indicate significance, p < 0.05, p < 0.01, p < 0.001, and p < 0.0001 
as indicated by *, **, ***, and ****, respectively.  
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Self-reported adherence to interventions at 28 days (capsule count)  
 Table 9 presents the adherence to interventions of those who completed the 28-
day study.  Forty-five capsule cards were returned to the investigator (CDB).  On 
average, 27.2 ± 1.4 capsules were taken by the participants.  Specifically, forty-three 
participants took the intervention as directed (i.e., 1 capsule per day); however, two 
participants took more than directed.  After identification, these participants were 
provided an additional capsule card and again verbally given specific instructions to 
administer one capsule by mouth at bedtime for the remainder of the study.  Two 
participants did not return the capsule card but verbally informed the investigator (CDB) 
that all capsules had been taken.  Statistical analyses revealed no significant differences 
between the two groups for mean number of capsules taken or adherence as directed.   
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Table 9    
Adherence to Interventions at 28 days (Capsule Count) 
Variable Total  Melatonin Placebo 
n (completed 28 days) 48 24 24 
Returned Cards, n 45 22 23 
Capsules Count    
Mean, SD  27.2 ± 1.4 27.5 ± 1.3 26.9 ± 1.5 
Adherence, n (%)    
As Directed 43 (89.6) 20 (83.3) 23 (95.8) 
> Directed  2 (4.2) 2 (8.3) 0 (0.0) 
Verbal Confirmation 2 (4.2) 1 (4.2) 1 (4.2) 
Unknown 1 (2.1) 1 (4.2) 0 (0.0) 
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Self-reported adverse events   
 Table 10 presents the self-reported adverse events experienced during the 28-day 
study.  To address any adverse events relating to the interventions, the participant was 
encouraged to report any adverse events to the investigator (CDB) or at the weekly 
assessments to identify any new symptoms experienced other than those at time of study 
entrance.  Twenty participants (28.6%) reported experiencing an adverse event.  The 
most reported adverse events were “fatigue/groggy/tired/sleepy,” “headache,” 
“nightmares/vivid dreams,” and “sleeplessness/wakefulness.”  From July to the end of 
January, the investigator observed a number of individuals at the center experiencing 
symptoms of the common cold; thus, the symptoms of the common cold are most likely 
not attributable to the intervention.  Statistical analyses revealed no significant 
differences between the two groups for number of participants reporting an adverse 
event.      
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Table 10    
Self-reported Adverse Events       
Variable Total Melatonin Placebo 
n  70 35 35 
Reported, n (%) 20 (28.6) 13 (37.1) 7 (20.0) 
Adverse Events, # 26 18 8 
Common Cold  2 2 0 
Diarrhea 2 0 2 
Fainted 1 1 0 
Fatigue/Groggy/Tired/Sleepy 6 4 2 
Headache 4 2 2 
Nausea 1 1 0 
Nightmares/Vivid Dreams 4 4 0 
Sleeplessness/Wakefulness 5 3 2 
Sleep Latency 1 1 0 
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Intention-to-treat: mean self-reported GAD-7 scores 
 Figure 3 presents the mean self-reported GAD-7 scores of the melatonin and 
placebo groups at baseline and each weekly assessment.  Values are mean ± SEM, GAD-
7 scores (0 – 21).  Higher scores indicate more severity of anxiety.  The two-way 
ANOVA was conducted to investigate score differences in intervention and time among 
participants.  The results revealed no significant interaction between factors (Intervention 
by Time), F (4, 283) = 0.6362, p = 0.6370, ω2 = 0.7571.  No significant main effect for 
intervention, F (1, 283) = 0.5794, p = 0.4472, ω2 = 0.1724 was determined.  However, the 
two-way ANOVA results revealed a significant main effect for time, F (4, 283) = 12.51, 
p < 0.0001, ω2 = 14.88.  Results of the Tukey post hoc test revealed no significant 
between group differences but revealed significant within group differences especially for 
Baseline to Day 28 for both groups (See Table 11).        
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Figure 3. The mean self-reported GAD-7 scores of the melatonin and placebo groups at baseline and each 
weekly assessment.  Values are mean ± SEM, GAD-7 scores (0 – 21).  Higher scores indicate more severity 
of anxiety.  The two-way ANOVA was conducted to investigate score differences in intervention and time 
among participants.  The results revealed no significant interaction between factors (Intervention by Time) 
and no significant main effect for intervention.  However, the results revealed a significant main effect for 
time.  The Tukey post hoc test revealed no significant between group differences but revealed significant 
within group differences especially for Baseline to Day 28 for both groups.  Melatonin (n = 35) and 
Placebo (n = 35).    
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Intention-to-treat: mean self-reported PHQ-8 scores 
 Figure 4 presents the mean self-reported PHQ-8 scores of the melatonin and 
placebo groups at baseline and each weekly assessment.  Values are mean ± SEM, PHQ-
8 scores (0 – 24).  Higher scores indicate more degree of depression.  The two-way 
ANOVA was conducted to investigate score differences in intervention and time among 
participants.  The results revealed no significant interaction between factors (Intervention 
by Time), F (4, 283) = 0.8085, p = 0.5206, ω2 = 0.9557.  No significant main effect for 
intervention, F (1, 283) = 0.2558, p = 0.6134, ω2 = 0.0756 was determined.  However, the 
two-way ANOVA results revealed a significant main effect for time, F (4, 283) = 12.97, 
p < 0.0001, ω2 = 15.34.  Results of the Tukey post hoc test revealed no significant 
between group differences but revealed significant within group differences especially for 
Baseline to Day 28 for both groups (See Table 11).  
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Figure 4. The mean self-reported PHQ-8 scores of the melatonin and placebo groups at baseline and each 
weekly assessment.  Values are mean ± SEM, PHQ-8 scores (0 – 24).  Higher scores indicate more degree 
of depression.  The two-way ANOVA was conducted to investigate score differences in intervention and 
time among participants.  The results revealed no significant interaction between factors (Intervention by 
Time) and no significant main effect for intervention.  However, the results revealed a significant main 
effect for time.  Results of the Tukey post hoc test revealed no significant between group differences but 
revealed significant within group differences especially for Baseline to Day 28 for both groups.  Melatonin 
(n = 35) and Placebo (n = 35). 
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Intention-to-treat: mean self-reported PSS-14 scores 
 Figure 5 presents the mean self-reported PSS-14 scores of the melatonin and 
placebo groups at baseline and each weekly assessment.  Values are mean ± SEM, PSS-
14 scores (0 – 56).  Higher scores indicate more degree of stress.  The two-way ANOVA 
was conducted to investigate score differences in intervention and time among 
participants.  The results revealed no significant interaction between factors (Intervention 
by Time), F (4, 283) = 0.3180, p = 0.8658, ω2 = 0.3666.  No significant main effect for 
intervention, F (1, 283) = 0.5188, p = 0.4719, ω2 = 0.1495 was determined.  However, the 
two-way ANOVA results revealed a significant main effect for time, F (4, 283) = 15.54, 
p < 0.0001, ω2 = 17.92.  Results of the Tukey post hoc test revealed no significant 
between group differences but revealed significant within group differences especially for 
Baseline to Day 28 for both groups (See Table 11).  
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Figure 5. The mean self-reported PSS-14 scores of the melatonin and placebo groups at baseline and each 
weekly assessment.  Values are mean ± SEM, PSS-14 scores (0 – 56).  Higher scores indicate more degree 
of stress.  The two-way ANOVA was conducted to investigate score differences in intervention and time 
among participants.  The results revealed no significant interaction between factors (Intervention by Time) 
and no significant main effect for intervention.  However, the results revealed a significant main effect for 
time.  Results of the Tukey post hoc test revealed no significant between group differences but revealed 
significant within group differences especially for Baseline to Day 28 for both groups.  Melatonin (n = 35) 
and Placebo (n = 35). 
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Intention-to-treat: mean self-reported PSSQ-1 sleep complaints scores  
 Figure 6 presents the mean self-reported PSSQ-1 sleep complaints scores of the 
melatonin and placebo groups at baseline and each weekly assessment.  Values are mean 
± SEM, PSSQ-1 scores (0 – 25).  Higher scores indicate more frequency of sleep 
complaints.  The two-way ANOVA was conducted to investigate score differences in 
intervention and time among participants.  The results revealed no significant interaction 
between factors (Intervention by Time), F (4, 283) = 0.3877, p = 0.8174, ω2 = 0.5059.  
No significant main effect for intervention, F (1, 283) = 0.5397, p = 0.4632, ω2 = 0.1761 
was determined.  However, the two-way ANOVA results revealed a significant main 
effect for time, F (4, 283) = 5.359, p < 0.0004, ω2 = 6.993.  Results of the Tukey post hoc 
test revealed no significant between group differences but revealed a significant within 
group difference for Baseline to Day 28 for only the melatonin group (See Table 11).  
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Figure 6. The mean self-reported PSSQ-1 sleep complaint scores of the melatonin and placebo groups at 
baseline and each weekly assessment.  Values are mean ± SEM, PSSQ-1 scores (0 – 25).  Higher scores 
indicate more frequency of sleep complaints.  The two-way ANOVA was conducted to investigate score 
differences in intervention and time among participants.  The results revealed no significant interaction 
between factors (Intervention by Time) and no significant main effect for intervention.  However, the 
results revealed a significant main effect for time.  Results of the Tukey post hoc test revealed no 
significant between group differences but revealed a significant within group difference for Baseline to Day 
28 for only the melatonin group.  Melatonin (n = 35) and Placebo (n = 35).    
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Intention-to-treat: mean self-reported PSSQ-1 sleep affecting daily life scores  
 Figure 7 presents the mean self-reported PSSQ-1 sleep affecting daily life scores 
of the melatonin and placebo groups at baseline and each weekly assessment.  Values are 
mean ± SEM, PSSQ-1 scores (0 – 32).  Higher scores indicate more effect on daily life.  
The two-way ANOVA was conducted to investigate score differences in intervention and 
time among participants.  The results revealed no significant interaction between factors 
(Intervention by Time), F (4, 283) = 0.3946, p = 0.8124, ω2 = 0.4941.  No significant 
main effect for intervention, F (1, 283) = 0.02420, p = 0.8765, ω2 = 0.007574 was 
determined.  However, the two-way ANOVA results revealed a significant main effect 
for time, F (4, 283) = 8.713, p < 0.0001, ω2 = 10.91.  Results of the Tukey post hoc test 
revealed no significant between group differences but revealed a significant within group 
difference for Baseline to Day 28 for only the melatonin group (See Table 11).  
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Figure 7. The mean self-reported PSSQ-1 sleep affecting daily life scores of the melatonin and placebo 
groups at baseline and each weekly assessment.  Values are mean ± SEM, PSSQ-1 scores (0 – 32).  Higher 
scores indicate more effect on daily life.  The two-way ANOVA was conducted to investigate score 
differences in intervention and time among participants.  The results revealed no significant interaction 
between factors (Intervention by Time) and no significant main effect for intervention.  However, the 
results revealed a significant main effect for time.  Results of the Tukey post hoc test revealed no 
significant between group differences but revealed a significant within group difference for Baseline to Day 
28 for only the melatonin group.  Melatonin (n = 35) and Placebo (n = 35).    
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Complete case: mean self-reported GAD-7 scores  
 Figure 8 presents the mean self-reported GAD-7 scores of the melatonin and 
placebo groups at baseline and each weekly assessment.  Values are mean ± SEM, GAD-
7 scores (0 – 21).  Higher scores indicate more severity of anxiety.  The two-way 
ANOVA was conducted to investigate score differences in intervention and time among 
participants.  The results revealed no significant interaction between factors (Intervention 
by Time), F (4, 230) = 0.3903, p = 0.8155, ω2 = 0.5176.  No significant main effect for 
intervention, F (1, 230) = 2.394, p = 0.1231, ω2 = 0.7939 was determined.  However, the 
two-way ANOVA results revealed a significant main effect for time, F (4, 230) = 16.91, 
p < 0.0001, ω2 = 22.43.  Results of the Tukey post hoc test revealed no significant 
between group differences but revealed significant within group differences especially for 
Baseline to Day 28 for both groups (See Table 11).        
 
 
 
 
 
 
 
 
 
 
 78 
 
Figure 8.  The mean self-reported GAD-7 scores of the melatonin and placebo groups at baseline and each 
weekly assessment.  Values are mean ± SEM, GAD-7 scores (0 – 21).  Higher scores indicate more severity 
of anxiety.  The two-way ANOVA was conducted to investigate score differences in intervention and time 
among participants.  The results revealed no significant interaction between factors (Intervention by Time) 
and no significant main effect for intervention.  However, the results revealed a significant main effect for 
time.  The Tukey post hoc test revealed no significant between group differences but revealed significant 
within group differences especially for Baseline to Day 28 for both groups.  Melatonin (n = 24) and 
Placebo (n = 24).    
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Complete case: mean self-reported PHQ-8 scores  
 Figure 9 presents the mean self-reported PHQ-8 scores of the melatonin and 
placebo groups at baseline and each weekly assessment.  Values are mean ± SEM, PHQ-
8 scores (0 – 24).  Higher scores indicate more degree of depression.  The two-way 
ANOVA was conducted to investigate score differences in intervention and time among 
participants.  The results revealed no significant interaction between factors (Intervention 
by Time), F (4, 230) = 0.3410, p = 0.8501, ω2 = 0.4588.  No significant main effect for 
intervention, F (1, 230) = 1.311, p = 0.2534, ω2 = 0.4409 was determined.  However, the 
two-way ANOVA results revealed a significant main effect for time, F (4, 230) = 16.16, 
p < 0.0001, ω2 = 21.74.  Results of the Tukey post hoc test revealed no significant 
between group differences but revealed significant within group differences especially for 
Baseline to Day 28 for both groups (See Table 11).  
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Figure 9. The mean self-reported PHQ-8 scores of the melatonin and placebo groups at baseline and each 
weekly assessment.  Values are mean ± SEM, PHQ-8 scores (0 – 24).  Higher scores indicate more degree 
of depression.  The two-way ANOVA was conducted to investigate score differences in intervention and 
time among participants.  The results revealed no significant interaction between factors (Intervention by 
Time) and no significant main effect for intervention.  However, the results revealed a significant main 
effect for time.  Results of the Tukey post hoc test revealed no significant between group differences but 
revealed significant within group differences especially for Baseline to Day 28 for both groups.  Melatonin 
(n = 24) and Placebo (n = 24). 
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Complete case: mean self-reported PSS-14 scores  
 Figure 10 presents the mean self-reported PSS-14 scores of the melatonin and 
placebo groups at baseline and each weekly assessment.  Values are mean ± SEM, PSS-
14 scores (0 – 56).  Higher scores indicate more degree of stress.  The two-way ANOVA 
was conducted to investigate score differences in intervention and time among 
participants.  The results revealed no significant interaction between factors (Intervention 
by Time), F (4, 230) = 0.2534, p = 0.9074, ω2 = 0.3395.  No significant main effect for 
intervention, F (1, 230) = 0.6704, p = 0.4137, ω2 = 0.2246 was determined.  However, the 
two-way ANOVA results revealed a significant main effect for time, F (4, 283) = 16.71, 
p < 0.0001, ω2 = 22.39.  Results of the Tukey post hoc test revealed no significant 
between group differences but revealed significant within group differences especially for 
Baseline to Day 28 for both groups (See Table 11).  
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Figure 10.  The mean self-reported PSS-14 scores of the melatonin and placebo groups at baseline and 
each weekly assessment.  Values are mean ± SEM, PSS-14 scores (0 – 56).  Higher scores indicate more 
degree of stress.  The two-way ANOVA was conducted to investigate score differences in intervention and 
time among participants.  The results revealed no significant interaction between factors (Intervention by 
Time) and no significant main effect for intervention.  However, the results revealed a significant main 
effect for time.  Results of the Tukey post hoc test revealed no significant between group differences but 
revealed significant within group differences especially for Baseline to Day 28 for both groups.  Melatonin 
(n = 24) and Placebo (n = 24). 
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Complete case: mean self-reported PSSQ-1 sleep complaints scores  
 Figure 11 presents the mean self-reported PSSQ-1 sleep complaints scores of the 
melatonin and placebo groups at baseline and each weekly assessment.  Values are mean 
± SEM, PSSQ-1 scores (0 – 25).  Higher scores indicate more frequency of sleep 
complaints.  The two-way ANOVA was conducted to investigate score differences in 
intervention and time among participants.  The results revealed no significant interaction 
between factors (Intervention by Time), F (4, 230) = 0.2352, p = 0.9183, ω2 = 0.3624.  A 
significant main effect for intervention, F (1, 230) = 5.817, p = 0.0167, ω2 = 2.241 was 
determined.  Also, the two-way ANOVA results revealed a significant main effect for 
time, F (4, 230) = 5.703, p = 0.0002, ω2 = 8.788.  Results of the Tukey post hoc test 
revealed no significant between group differences and no significant within group 
differences especially for Baseline to Day 28 for both groups (See Table 11).  
 
 
 
 84 
 
Figure 11. The mean self-reported PSSQ-1 sleep complaint scores of the melatonin and placebo groups at 
baseline and each weekly assessment.  Values are mean ± SEM, PSSQ-1 scores (0 – 25).  Higher scores 
indicate more frequency of sleep complaints.  The two-way ANOVA was conducted to investigate score 
differences in intervention and time among participants.  The results revealed no significant interaction 
between factors (Intervention by Time) but a significant main effect for intervention.  Also, the results 
revealed a significant main effect for time.  Results of the Tukey post hoc test revealed no significant 
between group differences and no significant within group differences for Baseline to Day 28 for the 
groups.  Melatonin (n = 24) and Placebo (n = 24).    
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Complete case: mean self-reported PSSQ-1 sleep affecting daily life scores  
 Figure 12 presents the mean self-reported PSSQ-1 sleep affecting daily life 
scores of the melatonin and placebo groups at baseline and each weekly assessment.  
Values are mean ± SEM, PSSQ-1 scores (0 – 32).  Higher scores indicate more effect on 
daily life.  The two-way ANOVA was conducted to investigate score differences in 
intervention and time among participants.  The results revealed no significant interaction 
between factors (Intervention by Time), F (4, 230) = 0.3359, p = 0.8536, ω2 = 0.4712.  
No significant main effect for intervention, F (1, 230) = 1.891, p = 0.1704, ω2 = 0.6631 
was determined.  However, the two-way ANOVA results revealed a significant main 
effect for time, F (4, 230) = 12.99, p < 0.0001, ω2 = 18.22.  Results of the Tukey post hoc 
test revealed no significant between group differences but revealed significant within 
group differences especially for Baseline to Day 28 for both groups (See Table 11).  
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Figure 12. The mean self-reported PSSQ-1 sleep affecting daily life scores of the melatonin and placebo 
groups at baseline and each weekly assessment.  Values are mean ± SEM, PSSQ-1 scores (0 – 32).  Higher 
scores indicate more effect on daily life.  The two-way ANOVA was conducted to investigate score 
differences in intervention and time among participants.  The results revealed no significant interaction 
between factors (Intervention by Time) and no significant main effect for intervention.  However, the 
results revealed a significant main effect for time.  Results of the Tukey post hoc test revealed no 
significant between group differences but revealed significant within group differences especially for 
Baseline to Day 28 for both groups.  Melatonin (n = 24) and Placebo (n = 24). 
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Mean difference and percent change from baseline to day 28  
 Table 11 presents the mean difference and percent change from Baseline to Day 
28 of each outcome measure of the interventions.  Values are mean difference (95% 
confidence interval) with significance indicated by asterisks.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 88 
Table 11   
Mean Difference and Percent Change from Baseline to Day 28 
Outcome Measure Melatonin Placebo 
GAD-7   
ITT   
Baseline ± SEM 10.37143 ± 0.835238 9.742857 ± 0.938748 
Day 28 ± SEM 3.375 ± 0.711735 4.833333 ± 0.926006 
Mean Difference 6.996 (2.935, 11.06)**** 4.910 (0.8483, 8.971)** 
% Change 67.46 50.39 
CC   
Baseline ± SEM 10.33333 ± 0.795432 10.54167 ± 0.970342 
Day 28 ± SEM 3.375 ± 0.711735 4.833333 ± 0.926006 
Mean Difference 6.958 (3.111, 10.81)**** 5.708 (1.861, 9.556)*** 
% Change 67.33 54.15 
PHQ-8   
ITT   
Baseline ± SEM 11.77143 ± 0.914942 10.74286 ± 0.833483 
Day 28 ± SEM 4.75 ± 0.984021 5.541667 ± 0.947879 
Mean Difference 7.021 (2.844, 11.20)**** 5.201 (1.023, 9.379)** 
% Change 59.65 48.42 
CC   
Baseline ± SEM 11.41667 ± 0.948247 11.875 ± 0.788603 
Day 28 ± SEM 4.75 ± 0.984021 5.541667 ± 0.947879 
Mean Difference 6.667 (2.559, 10.77)**** 6.333 (2.225, 10.44)**** 
% Change 58.39 53.33 
PSS-14   
ITT   
Baseline ± SEM 31.85714 ± 1.207221 30.05714 ± 1.252857 
Day 28 ± SEM 21.29167 ± 1.594237 21.20833 ± 1.91578 
Mean Difference 10.57 (4.172, 16.96)**** 8.849 (2.455, 15.24)*** 
% Change 33.17 29.44 
CC   
Baseline ± SEM 31.79167 ± 1.200392 30.41667 ± 1.27656 
Day 28 ± SEM 21.29167 ± 1.594237 21.20833 ± 1.91578 
Mean Difference 10.50 (4.101, 16.90)**** 9.208 (2.810, 15.61)*** 
% Change 33.03 30.27 
PSSQ-1   
Sleep Complaints   
ITT   
Baseline ± SEM 16.57143 ± 1.031671 15.4 ± 1.118372 
Day 28 ± SEM 10.08333 ± 1.490206 11.79167 ± 1.220268 
Mean Difference 6.488 (0.7428, 12.23)* 3.608 (-2.137, 9.354) 
% Change 39.15 23.43 
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CC   
Baseline ± SEM 15.45833 ± 1.066694 16.41667 ± 0.99429 
Day 28 ± SEM 10.08333 ± 1.490206 11.79167 ± 1.220268 
Mean Difference 5.375 (-0.1545, 10.90) 4.625 (-0.9045, 10.15) 
% Change 34.77 28.17 
Quality of life   
ITT   
Baseline ± SEM 16.00 ± 1.32589 14.4 ± 1.394587 
Day 28 ± SEM 7.916667 ± 1.510731 8.625 ± 1.466797 
Mean Difference 8.083 (1.735, 14.43)** 5.775 (-0.5736, 12.12) 
% Change 50.52 40.10 
CC   
Baseline ± SEM 15.95833 ± 1.288727 15.75 ± 1.234343 
Day 28 ± SEM 7.916667 ± 1.510731 8.625 ± 1.466797 
Mean Difference 8.042 (2.110, 13.97)*** 7.125 (1.194, 13.06)** 
% Change 50.39 45.24 
Mean difference (Baseline - Day 28).   
Percent change [(Baseline - Day 28) / Baseline] * 100  
Values in parentheses are 95% confidence interval.  
ITT = Intention-to-treat; CC = Complete case  
Asterisks indicate significance, p < 0.05, p < 0.01, p < 0.001, and p < 0.0001 
as indicated by *, **, ***, and ****, respectively.  
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Contingency table analysis and strength of association 
 Table 12 presents the results of the Fisher’s exact test (two-tailed, CI 95%) and 
the strength of association reported as relative risk (95% CI) of the change following the 
intervention.  No significant differences were detected.  All confidence intervals of the 
strength of association included the null value of 1, thus concluding there exists 
insufficient evidence to suggest that the interventions were significantly different.    
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Table 12   
Contingency Table Analysis and Strength of Association 
Outcome 
Measure P value Relative Risk (95% CI) 
GAD-7 1.0000 1.063 (0.6466 to 1.746) 
PHQ-8 0.6279 1.231 (0.7014 to 2.160) 
PSS-14 0.5401 0.6250 (0.2260 to 1.724) 
PSSQ-1   
Complaints 0.5613 1.500 (0.5973 to 3.767) 
Daily life 0.7972 1.200 (0.5980 to 2.408) 
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DISCUSSION 
Based upon the results of the systematic review, three identified studies 
investigated the use of melatonin in those recovering from alcohol dependency.  All three 
studies investigated the effect of melatonin on sleep measures while only one study 
included assessments of its antidepressant and anxiolytic effects.  Therefore, clinical 
investigations into the use of melatonin as a treatment for depression, anxiety, stress, and 
sleep difficulties in those recovering from illicit and non-illicit drug dependency is 
limited and more studies are warranted.  This is the first and largest randomized, double-
blind, placebo-controlled trial assessing the effects of melatonin upon post-acute 
withdrawal among males in a residential treatment program.  The purpose of the study 
was to assess the effect of 5 mg melatonin compared to placebo as an adjuvant treatment 
along with their current pharmaco- and behavioral therapies for 28 days on weekly self-
reported severity of anxiety, depression, stress, and sleep complaints as well as how sleep 
is affecting daily life in a sample of males in recovery from chemical dependency at a 
single, residential treatment site.   
Even though the results for all outcome measures revealed statistically significant 
within-groups differences over time for both groups, post hoc analyses revealed the study 
lacked sufficient evidence to demonstrate statistically significant between-group 
differences for these measures.  Additionally, contingency table analysis as well as the 
relative degree of association between response for participants who are taking melatonin 
compared to those taking placebo (i.e., relative risk) revealed no significant strength of 
association between the groups (i.e., confidence interval included null value of 1) when 
considering worst case for the loss to follow-up.  Overall, the various analyses indicated 
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there exists insufficient evidence to suggest that melatonin and placebo were significantly 
different, and it may be concluded, based upon the study sample, design, and its 
limitations, the effect of melatonin on the assessed measures was no different than 
placebo.   
 The mean age of the sample was 40.4 ± 11 years (range 21 – 65 and median 39) 
and consisted mostly of those who identified as white (70%), single (74.3%), and with an 
education level of high school/G.E.D. or less (77.1%).  Black/African-American 
enrollment was at 24.3%.  The sample was similar to the racial demographics reported in 
the Treatment Episode Data Set (TEDS) of nationwide admissions into substance abuse 
treatment facilities where it was reported that Whites and African-Americans account for 
60% and 21%, respectively (9).  The participants have a variety of medical issues with 
88.6% reporting a medical condition and also present with multiple medication use with 
an average of 3.5 ± 2.2 (range 0 – 11 and median 3) medications.  Interestingly, a total of 
75 different medications were prescribed including antiviral (HIV/AIDS), cardiovascular, 
central nervous, endocrine, gastrointestinal, respiratory, nutraceuticals (i.e., vitamins, 
minerals, and nutritional supplements), and other medications with 157 total medications 
being prescribed for treating conditions of the central nervous system.  Collectively, the 
histories suggest that these individuals experience a tremendous burden of neurological 
disorders such as cervical or lumbar disc radiculopathies and mood disorders.  As 
detailed, 91.4% reported a history of diagnosed mental health conditions.  Of those 
reported, depression followed by anxiety were the most reported with 62.5% reporting 
co-occurring depression and anxiety with or without other mental health conditions.  The 
prevalence of mental health issues is substantially higher in the study sample compared to 
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the U.S. general population.  This difference may be due to the lack of psychiatric 
services for the population at the center resulting in over diagnosis by non-psychiatric 
physicians.  As stated in 2013 NSDUH report, 3.2% of adults had both a substance use 
disorder and any mental illness and 1% of adults had both a substance use disorder and a 
serious mental illness (5).  Of interest, 24.3% of participants reported a history of 
hepatitis.  However, based upon the expected medication usage for the 28 days, no 
medications specific to hepatitis treatment were reported.  Unfortunately, the study did 
not investigate if these participants had undergone treatment in the past or were expecting 
to be treated in the future.   
To add to their future health and medical burden, 90% of the participants reported 
use of nicotine delivery products with cigarettes being the most favored.  Caffeinated 
beverage consumption was high with coffee being preferred.  Of note, the center had a 
coffee maker, tea packets, and soda dispensing machine available for resident use.  It may 
be surmised that the residents are substituting or maintaining use of more socially 
acceptable stimulants (nicotine and caffeine) while trying to remain abstinent from much 
harder drugs.  Regarding fitness activities, about three quarters of the participants did 
some form of exercise during the week with weight training being the most preferred.  
One reason for such a high use is the availability of an onsite recreation room that housed 
weight training equipment.    
Regarding chemical dependency, the participants reported a history of multiple 
illicit and non-illicit drug use.  The most frequently reported number of drugs used was 
two with a history of alcohol use being the most prevalent (60%); specifically 15.7% 
reported abuse of alcohol only while 44.3% abused alcohol and another drug; these 
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findings vary from the TEDS report that stated 41.4% of admissions sought treatment for 
alcohol abuse (23.1% alchohol only) and 18.3% of those for abusing alcohol with another 
drug.  Reported stimulant abuse was higher than the TEDS reported findings of 17.8% for 
cocaine and other stimulants.  In line with the TEDS report of 20% of those seeking 
treatment sought treatment for heroin and other opiates, 20% of the sample reported a 
history of abuse of heroin and opiate drugs. 
History of prior melatonin use was surveyed to investigate if more participants 
were willing to participate that may have had a positive experience of use, in contrast to 
those not willing to participate who may have had an adverse experience.  As reported, 
almost half of the sample (42.9%) indicated prior use with 100% using it for treating their 
sleep difficulties, and 70.0% believed it helped.  Overall, about 30.0% out of all the 
participants had a favorable opinion of melatonin at study entrance.  Even though it is 
readily available on store shelves, over half of the participants (53.3%) received 
melatonin from a clinician mostly in a hospital or rehabilitation center at reported doses 
of 3 to 10 mg.  Interestingly, although there is a body of evidence that suggests that 
melatonin is efficacious for sleep, there is a paucity of evidence-based literature of its 
efficacy in this population. 
Even though it is difficult to specifically ascertain issues with study masking or 
efficacy of the intervention, the belief of the participant completing 28 days regarding 
intervention allocation was assessed by asking “Do you believe you were taking 
melatonin?”  The rationale for the inquiry was because 30.0% of the participants had a 
positive prior melatonin experience and may have remained cognizant of its effects.  
Surprisingly, thirty-four participants (70.8%) believed the assigned intervention taken 
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was melatonin.  To provide more evidence of their belief, most of the returned capsule 
cards were missing the two extra provided capsules suggesting the participants kept the 
capsules.  Because of the high percentage of participants believing the assigned 
intervention taken was melatonin, twenty-two participants (45.8%) correctly identified 
the intervention while 26 participants (54.2%) were incorrect.  Interestingly, 12 
participants (25.0%) who incorrectly identified the provided intervention reported a prior 
history of melatonin use.  It would seem that a prior history of use would suggest the 
ability to recall similarities between the previous effect and the current effect; however 
this appeared to not be the case.   
Although adherence, as determined by capsule counts, was very high, questions 
about the true adherence remain.  For example, one individual was assessed to Day 21 
but left the center, and the capsule card located in the room was untouched.  Potentially, 
this capsule card could have been returned to the investigator devoid of capsules by 
disposing of the capsules before entering the designated room for Day 28 assessment.  
Also, the nightly administration of the capsules was the responsibility of the participant 
and no direct observation of capsule administration by staff or investigators was 
conducted.      
To assess for adverse events, the participants were prompted to report any new 
symptoms during the past week; however, because of the nature of the participants, they 
may have underreported events out of the unfounded fear of being withdrawn from the 
study or being accustomed to not revealing too much information (i.e., incriminate 
oneself) suggesting a potential reporting bias.  Overall, the adverse events were similar 
between the interventions except for a tendency of melatonin to induce more 
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nightmares/vivid dreams and next day fatigue/grogginess which are commonly associated 
with melatonin use.  One reason for the increase in next day effects may be attributed to a 
lack of established bedtime by the study or the center.  Therefore, the experimental 
intervention may have been taken later in the night; thus, the 5 mg dose may have 
resulted in a carryover effect to late morning.  Importantly, melatonin levels are 
influenced by various classes of drugs (e.g., psychotropic medications) that induce, 
inhibit, or act as a substrate of CYP1A2 (42).  Thus, there exists the possibility that the 
prescribed medications may have affected the metabolism of melatonin.  Even though 
majority of participants had prior history of melatonin use, they expressed a keen interest 
and concern about the potential adverse events associated with melatonin, and its 
potential impact in their recovery.   
Both groups resulted in a rapid improvement in measured outcomes from 
Baseline to Day 28 with the sharpest improvement occurring from Baseline to Day 7.  
This improvement may be attributed to the individual being in a stable, supportive 
environment, having access to necessary resources, as well as being provided pharmaco- 
and behavioral therapies.  Because the study incorporated weekly measures in an effort to 
allow for a detection of an effect of melatonin on a weekly basis instead of at the final 
endpoint of 28 days, the impact of the effect of melatonin compared to placebo on 
measured outcomes at each weekly assessment was further investigated by conducting 
two-way ANOVA (Intervention by Outcome) with the complete cases.  In aggregate, no 
between-group differences were detected (Data not shown).  To further support the 
results of the intention-to-treat analyses as well as to assure that the sample of those 
completing the study were similar in outcomes (i.e., results not affected by loss to follow-
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up), complete case analyses with two-way ANOVA (Intervention by Time) for all 
outcomes were also performed.  Overall, both the intention-to-treat and complete case 
analyses generated similar results (i.e., no between group differences for all outcomes).  
Additionally, the proportion of those having a response for each group revealed no 
significant strength of association between the groups (i.e., confidence interval included 
null value of 1) considering worst case for the loss to follow-up.   
Limitations and generalizability 
Because the study was conducted at the Salvation Army Harbor Light Center in 
Pittsburgh, PA, it was not a multicenter study but a single center study, and the center has 
a unique approach to treatment where men are cared for physically, mentally, and 
spiritually in order to allow each man to realize his worth, value, and personhood.  Also, 
the study was age, gender, and geographically restricted to males over the age of 18 who 
are residents of Allegheny County with a valid Pennsylvania identification; thus 
investigations into the effects in adolescents, females, or those residing outside of 
Allegheny County were not possible.  Because sampling and enrollment occurred from 
July 2015 to December 2015, there existed the potential that time of year may have 
influenced endogenous melatonin duration of action because research has shown that 
duration of action of endogenous melatonin is affected by the season due to variation in 
light exposure (32).  Thus, future studies may want to consider limiting enrollment to one 
season.  Most of the participants in the study were enrolled within a week to two weeks 
upon entrance into the center.  Thus, there exists the possibility that some of the 
participants may have been still experiencing the acute phase of withdrawal instead of 
being in post-acute withdrawal.  Unfortunately, the study did not include assessment of 
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levels of melatonin thus limiting the knowledge of levels of melatonin in the participants 
at inclusion and upon completion of study.  If levels of melatonin were assessed, for 
example at each follow-up, then a correlation between the levels of melatonin to outcome 
could be performed.  Additionally, the data obtained from assessing levels of melatonin 
could be used to provide insight into why participants responded or not.  Also, the levels 
would provide additional data for intervention adherence along with the capsule counts.  
The inclusion and exclusion criteria in the study was broad and did not limit eligibility 
for type of chemical dependency, mental health status, prescribed medication (e.g., 
antidepressant, anxiolytic, and/or sedating psychotropic drugs), prior melatonin use, 
and/or medical conditions.  Once accepted into the center, the residents follow a daily 
schedule that includes group and individual therapy sessions, meals, and activities.  
However, it must be emphasized that individuals at the center are heterogeneous and 
present with a complex history of chemical dependency along with potentially co-
occurring mental health and medical conditions, limited formal education, societal issues, 
the episodic nature of symptoms of PAWS, and multiple medication use that adds to the 
difficulty of studying the effect of melatonin on the measured outcomes.  Even though 
the outcomes measured were conducted with readily available, brief, and valid 
instruments, a few individuals had requested help during survey completion; thus, more 
individuals may have had needed help but were self-conscious as not to inquire for help.  
As aforementioned, the instruments used are valid and reliable for measuring self-
reported psychiatric symptoms, the literature reporting the validity and reliability in use 
with a population in recovery is limited thus adding difficulty of generalizability to this 
population (74, 75).  Any one of these could potentially impact the outcomes (i.e., 
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improvement) thereby reducing between-group differences or the potential therapeutic 
effect of melatonin leading to a possible Type II error, failure to reject the null hypothesis 
(i.e., accepting the null hypothesis) that is false.  Group algorithms and subsequent 
subgroup analyses were not conducted because of the lack of significant between-group 
differences as well as the limited sample number thereby these analyses would have been 
underpowered.   
In retrospect, the study would have been aided by the inclusion of a therapy alone 
arm to assess the effects of therapy alone without the adjuvant addition of the 
interventions.  The milieu of a total therapeutic environment may have accounted for the 
decrease observed in the measured outcomes independent of the effect of treatment or 
placebo.  While reading the consent form, the participants were informed of the 
likelihood of being assigned to either the melatonin or placebo group potentially biasing 
the perception of intervention assignment and the outcomes.  Because of the high 
percentage of belief the intervention taken was melatonin, the participants may have had 
or developed through further research during participation, ideas of the efficacy and value 
of melatonin as a treatment.  Moreover, spillover effect may have occurred because 
participants had the potential to freely discuss the effects of the interventions among their 
fellow residents potentially biasing their perception of efficacy.  From observation, the 
participants were actively aware of the pharmacology and adverse events associated with 
their prescribed pharmacotherapies.  Because of the overall residential and rehabilitative 
environment of the center as well as the various types of support provided by it, there 
exists the possibility that participants may be motivated to demonstrate improvement in 
symptoms over time to maintain residency at the center.  This would bias the results by 
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falsely demonstrating an improvement over time as well as masking any true effect of the 
experimental intervention, if one exists.    
It is difficult to assess the impact of the psychotropic medications on the 
measured outcomes because the study lacked questions addressing medication indication 
(e.g., sleep versus mood disorders) and the length of time the individual has been taking 
the medication.  Although the participant histories form asked for current medication and 
its dosage regimen, it was difficult for a few individuals to recall the list of prescribed 
medications as well as the dosage regimen.  Considering medications such as 
antidepressants may take weeks before therapeutic effect is observed, there is uncertainty 
as to duration of therapy and their adherence.  The improvement in outcome measures 
may be result of the efficacy of psychotropic medications thereby reducing between-
group differences and/or potentially attenuated or masked the effect of melatonin, if any.  
Another possibility is that the efficacy is similar between melatonin and psychotropic 
medications, and the generated data did not suggest a potentiating effect with 
concomitant use.  
The outcomes were measured weekly (Monday or Thursday) and was based on 
day of enrollment.  Analysis revealed no between-group differences comparing those 
surveyed on Monday or Thursday (Data not shown).  Importantly, each designated time 
frame indicated on the surveys was changed to “over the last seven days” for the follow-
up times.  This change was implemented to alleviate the influence of recall bias.  Because 
the individuals were assessed with subjective, self-reported measures, there is the 
potential for recall bias.  For example, the individuals may be more acutely aware of how 
they were feeling on those days closer to the assessment than earlier days.  Moreover, 
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their physical and mental state may have influenced their ability to recall, thus biasing the 
subjective measures.  Self-reported measures, in part, rely on the subjective experiences 
of the participant and as such bring into question the reliability of such measures.  No 
objective measures were conducted to complement the self-reported measures especially 
using physiological measures; specifically for example, assessment of sleep with 
polysomnography, which would have been not feasible at the center, or wrist actigraphy.  
Thus, no correlations between subjective and objective measures were able to be 
performed to determine accuracy of the self-reported measures.   
Because the participant histories as well as the self-reported outcome measures 
may not have been completed accurately, the collected data is susceptible to recall bias as 
well as the mood or willingness/openness of the participant to provide accurate 
information, and as such, questions remain as to the reliability and validity of the data.  
However, no significant between-group differences were detected for all outcome 
measures suggesting that any bias with regards to accuracy were similar.  Also, inter-
individual variability in the outcome measures may affect the detection of between-group 
differences.  Although underpowered, no between-group differences were detected after 
conducting additional analyses, excluding those participants with either mild anxiety or 
depression (Data not shown).  A deeper investigation into how the high belief that the 
intervention taken was melatonin may have influenced the results is warranted.   
As aforementioned, previous literature investigating the use of melatonin is 
limited and suffers from either lack of placebo control, small sample size, or sample 
consisting of only abstinent alcohol dependent individuals.  Because of the limited data, 
the power analysis was calculated with a small effect size in order to enroll a larger 
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number of individuals to allow for adequate power to capture a small melatonin effect (> 
0.15).  Conversely, if larger effect sizes were selected, the number of individuals needed 
to be enrolled would have been less.  Even though there were no significant between-
group differences, the mean differences from Baseline to Day 28 of the melatonin group 
were larger for all outcomes compared to placebo suggesting a potential very small effect 
of melatonin that may be detectable with a larger “n.”    
The study lacked a run-in period to help address if exclusions needed to be made; 
for example, participants not adhering to prescribed medications, potential to disregard 
study protocol, or at a high risk for loss to follow-up.  Even though the power analysis 
included an adjustment for a predicted loss to follow-up of <20%, the loss to follow-up 
was 31.4% suggesting the study may be slightly underpowered.  Based upon the returned 
probability values, none of the between-group comparisons closely trended toward 
statistical significance.  Coincidentally, both groups had the same loss to follow-up.  The 
rate of loss to follow-up was consistent throughout the weeks with the highest occurring 
between Day 14 and Day 21 for both groups.  Loss to follow-up due to drug relapse was 
the highest at 45.5% suggesting the increased difficulty in maintaining abstinent even 
being in a supportive environment and provided needed resources.  Those that relapsed 
were detected to be under the influence of alcohol, benzodiazepines, heroin, or opiates.  
Two participants relapsed on benzodiazepines.  Strikingly, only four participants self-
reported benzodiazepine history.  The reason may be attributed to the patient history not 
directing addressing benzodiazepine use but indirectly through the term “Other.”  Of 
those who relapsed, a higher prevalence of heroin, opiates, and marijuana usage, but 
lower usage of alcohol was reported compared to the sample.  Also, mental health 
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disorders such as anxiety, bipolar as well as being comorbid for ≥2 were more prevalent.  
Another factor contributing to the loss to follow-up was administrative rule/policy 
violations possibly due to the center having a close to zero tolerance approach to 
violations.  Melatonin and placebo appeared to be well tolerated and each group had only 
one individual withdrawing due to an adverse event.  The individual lost to follow-up due 
to adherence with intervention is the same individual who was determined to not be 
taking the study intervention after discovery of the full capsule card upon leaving the 
center shortly after completing Day 21.  Only the Baseline data was included in the 
analyses.  Unfortunately, one individual who was out on a weekend pass given by the 
center was discovered deceased on a street in Pittsburgh.  The event leading to cause of 
death was still under investigation at time of study conclusion, but it was suggested that it 
was a possible drug overdose.  Because of the ambiguity, loss to follow-up was recorded 
as “Death” but not “Relapse.”  It is unlikely that melatonin may have influenced the 
potential drug relapse leading to death or death, in general.  Relapse rates were the same 
between the interventions, and melatonin has a high margin of safety.  Block 
randomization with a block size of four was utilized to ensure equal treatment allocation, 
but a larger block size could have been used to ensure greater unpredictability as to 
treatment allocation.   
Positively, the study met the recruitment and eligibility goal of 70 individuals in a 
time frame of six months.  Unfortunately, a motivating factor may have been the weekly 
financial compensation.  These individuals enrolled at the center tended to be of lower 
socioeconomic status and without current earning power (i.e., without a source of 
 105 
income).  Therefore, enrollment in the study provided access to funds that allowed them 
to purchase items such as cigarettes, an unintended consequence.   
Future directions 
Possible future directions include a study design that is multicenter, the inclusion 
of a therapy only arm, assessing various doses and timelines, assessing effects in 
adolescents or females, assessing levels of melatonin at inclusion and study completion, 
assessing nocturnal levels of melatonin, or limiting inclusion based on prescribed 
medications, mental health status, medical conditions, prior melatonin use, and/or a 
specific chemical dependency.  Additionally, more clearly defined medication histories 
could be considered when enrolling participants.  Future studies may incorporate a 
protocol that ensures participants are actively taking the intervention nightly as well as 
consider establishing a specified bedtime range.  If the effect of melatonin is indeed very 
small, future studies should enroll a larger sample.  Also, it is recommended that a future 
power analysis include adjusting for at least a loss to follow-up greater than 30%.  
Because of the loss to follow-up was the highest between Day 14 and Day 21 for both 
groups, a study design considering a run-in may want to include a run-in length of at least 
two weeks.     
Conclusions 
Based upon the review of the literature, this is the first and largest randomized, 
double-blind, placebo-controlled trial assessing the effects of melatonin upon post-acute 
withdrawal among males in a residential treatment program.  The purpose of the study 
was to assess melatonin as an adjuvant treatment along with their current pharmaco- and 
behavioral therapy for 28 days on weekly self-reported severity of anxiety, depression, 
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stress, and sleep complaints as well as how sleep is affecting daily life in a sample of 
individuals in recovery from chemical dependency at a single, residential treatment site.  
In summary, the various analyses indicated there exists insufficient evidence to suggest 
that the melatonin and placebo were significantly different, and it may be concluded, 
based upon the study sample, design (e.g., inclusion and exclusion criteria) and 
limitations, the effect of melatonin on the assessed self-reported outcome measures was 
no different than taking placebo.  However, due to the heterogeneity of the participants as 
evidenced by the participant histories or by chance alone, there exists a possibility of a 
Type II error that must be considered and not overlooked.   
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APPENDIX 
 Capsule content was independently confirmed by the laboratory of Kevin J. 
Tidgewell, Ph.D. (Assistant Professor of Medicinal Chemistry, Graduate School of 
Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA) using high performance 
liquid chromatography.  The laboratory was blinded/masked as to intervention group of 
capsules provided.  Results of analysis is below: 
Cap Area (210) Height (210)   Area (222) Height (222) 
1 139.9546 71.647  144.1421 78.336 
1 139.5083 74.768  145.025 81.618 
1 139.2811 75.171  144.4363 82.393 
Avg. 1 139.5813333 73.862   144.5344667 80.78233333 
25 89.4659 48.61  96.1752 53.47 
25 89.1073 50.113  95.9579 55.13 
25 90.3399 50.553  96.9673 55.613 
Avg. 25 89.6377 49.75866667   96.3668 54.73766667 
27 0 0  0 0 
27 0 0  0 0 
27 0 0  0 0 
Avg. 27 0 0   0 0 
41 99.1313 55.18  109.4784 60.998 
41 98.5686 56.892  109.1269 62.9 
41 98.7854 57.271  109.4738 63.352 
Avg. 41 98.82843333 56.44766667   109.3597 62.41666667 
42 0 0  0 0 
42 0 0  0 0 
42 0 0  0 0 
Avg. 42 0 0   0 0 
60 0 0  0 0 
60 0 0  0 0 
60 0 0  0 0 
Avg. 60 0 0   0 0 
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 210 nm   222 nm     
 Area Height  Area Height  
Average/
pill 
St. 
Dev./pill 
Cap 1 [c] 
67.158
15 
64.341
4  
63.882
76 
64.037
77  
64.85501
86 
1.547191
5 
Cap 25 [c] 
43.057
57 
43.371
03  
42.789
89 
43.471
86  
43.17258
967 
0.310177
82 
Cap 41 [c] 
47.492
61 
49.190
59  
48.479
55 
49.535
51  
48.67456
459 
0.902322
42 
         
Average 
52.569
44 
52.301
01  
51.717
4 
52.348
38    
St. Dev. 
12.827
32 
10.825
67  
10.912
84 
10.567
56    
         
Average (all) 
52.234
06        
St. Dev. (all) 
9.6586
65        
         
Average of Averages 
(J7 - N7) 
52.234
06        
St. Dev. (J7-N7) 
0.3637
63        
 
Results of capsule content in milligrams for melatonin group 
41.6 comes from ug/mL melatonin/pill 
    
41.6ug/ml = average/ tab  
5mg mel  X  
    
7.800481 mg of melatonin: Capsule 1 
5.192308 mg of melatonin: Capsule 25 
5.853365 mg of melatonin: Capsule 41 
 
 
 
 
    
